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ABSTRACT
Osteoblasts form bone and regulate the activity of other bone cells. Lysophosphatidic 
acid (LPA) is a lipid mediator that, in other systems, stimulates cell proliferation, survival 
and migration. We investigated LPA signaling and function in osteoblasts. Transcripts 
encoding multiple LPA receptors were identified. LPA induced transient elevation of 
cytosolic calcium ([Ca ];) in primary osteoblasts and UMR-106 osteoblast-like cells,
effects that were attenuated by pertussis toxin, implicating Gj. Moreover, [Ca2+]j 
elevation was found to arise by release from intracellular stores. An LPAi receptor 
antagonist blocked bone formation in cultures of primary osteoblasts. Finally, LPA 
induced membrane blebbing in MC3T3-E1 osteoblast-like cells -  a process that was 
sensitive to inhibition of Rho-associated protein kinase or chelation of cytosolic calcium. 
Thus, LPA activates calcium-mobilizing receptors in osteoblastic cells to induce 
morphological changes. As well, LPA promotes bone formation in vitro. In vivo, LPA 
may regulate osteogenesis in an autocrine or paracrine manner.
Keywords -  Alkaline phosphatase, Blebbing, Bone formation, Calcium, Gj, Ki 16425, 
LPA, LPAj, Lysophosphatidic acid, Osteoblast, Osteogenesis, Pertussis toxin, Rho- 
associated protein kinase, Thapsigargin, VPC32183, Y-27632.
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INTRODUCTION AND LITERATURE REVIEW
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1.1 Chapter Summary
The osteoblast, a mesenchymal bone-forming cell, plays a fundamental role in skeletal 
development and bone remodeling (Harada and Rodan 2003). It is suggested that 
disrupted osteoblast function is associated with pathogenesis of diseases such as 
osteoporosis, periodontitis, and bone cancer metastases (Soltanoff et al. 2009). 
Lysophosphatidic acid (LPA) is a potent bioactive phospholipid known to influence 
normal development, immune responses and tumour development and progression 
(Jankowski 2011; Mills and Moolenaar 2003). This chapter provides an overview of the 
development, structure and physiology of bone, LPA synthesis and receptors, and current 
knowledge about LPA and bone biology.
1.2 Bone Physiology
1.2.1 Bone Composition
Bone is a dynamic connective tissue, composed of metabolically active cells 
integrated into a mineralized extracellular matrix (Kalfas 2001). Organic and inorganic 
elements constitute bone tissue, contributing together to the unique properties of bone 
(Rho, Kuhn-Spearing, and Zioupos 1998).
The inorganic component of bone matrix is primarily hydroxyapatite mineral 
crystals [Caio(P04)6(OH)2], providing rigidity to the bone matrix. Bone mineralization 
occurs by deposition of hydroxyapatite crystals into an organic extracellular matrix 
produced by osteoblasts (Hunter and Goldberg 1993). In addition, bone mineral contains 
some carbonate, fluoride, and magnesium, collectively known as poorly crystalline 
carbonate-substituted apatite (Grey et al. 2001).
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The organic component of the extracellular matrix acts as a framework for 
mineralization providing tensile strength and is composed primarily of type I collagen, 
including variable quantities of type III, and V collagen (Ashhurst, Ashton, and Owen 
1990; Buckwalter and Cooper 1987; Young 2003). Non-collagenous proteins comprise 
the remaining portion of the matrix proteins including proteoglycans (versican, decorin 
and biglycan), and glycoproteins (osteocalcin, osteonectin, osteopontin/bone sialoprotein) 
(Dickson and Bagga 1985).
The cellular components of bone include osteogenic precursor cells, osteoblasts, 
osteocytes, and osteoclasts (Kalfas 2001). Osteogenic precursor cells are mesenchymal 
stem cells that have the potential to differentiate into mature osteoblasts. Metabolically 
active, bone-forming osteoblasts are involved in bone matrix (osteoid) synthesis and 
mineralization (Johnson et al. 2000). Moreover, osteoblasts have the ability to regulate 
the resorptive activity of osteoclasts (Lanyon 1990). Current knowledge of the factors 
that regulate osteoblast differentiation (osteoblastogenesis) and function are discussed in 
section 1.2.3.
As the process of bone formation nears completion, some mature osteoblasts are 
encased within the mineralized matrix and are converted into osteocytes (Kalfas 2001). 
Osteoclasts, bone resorbing cells, are instrumental in bone remodeling and maintaining 
plasma serum mineral homeostasis (Caetano-Lopes, Canhao, and Fonseca 2007; Harada 
and Rodan 2003; Kalfas 2001). These cells release hydrochloric acid and proteases, 
dissolving the inorganic and organic bone matrix, creating an erosive pit and releasing 
calcium and phosphate (Kalfas 2001; Vaananen et al. 2000).
In mature bone tissue, bone removal and formation occur continuously via the
4
coordinated action of osteoclasts and osteoblasts, respectively. Taken together, these 
processes constitute bone remodelling. Coordinated bone remodeling is critical for 
maintaining bone mass, an imbalance between resorption and formation is implicated in 
various metabolic bone diseases (Rodan 2003).
1.2.2 Function of Bone
Varied bone architecture contributes to the ability of bone to perform diverse 
structural and metabolic functions. Structurally, bone protects internal organs and serves 
as an attachment point for muscle, permitting biomechanical function. In addition, bone 
provides a protective niche for the highly vascular bone marrow tissue (Rho, Kuhn- 
Spearing, and Zioupos 1998). The high turnover rate of trabecular bone is indicative of its 
metabolic function (Hadjidakis and Androulakis 2006). Metabolically, bone contributes 
to the circulatory and immune systems, and acts a reservoir for calcium and phosphorous, 
in turn helping to maintain ion homeostasis in the plasma (Hadjidakis and Androulakis 
2006). As a metabolically active organ, bone undergoes remodeling throughout life, a 
dynamic process involving a delicate balance between bone resorption and formation 
(Hadjidakis and Androulakis 2006; Raisz 1999). Remodeling serves to maintain 
mechanical integrity and repair microdamage in the bone matrix, as well as playing an 
important role in maintaining plasma calcium homeostasis (Raisz 1999). More details on 
bone remodeling are provided in section 1.2.5.
1.2.3 Bone Formation (Osteogenesis)
Osteogenesis and ossification are both terms used for the process of bone 
formation. During embryogenesis, bone can develop from two processes: endochondral 
ossification and intramembranous ossification. Long bones develop through
5
endochondral ossification; whereas flat bones are developed primarily by 
intramembranous ossification. Intramembranous ossification is the formation of bone 
without a cartilage template involving the proliferation of mesenchymal cells that 
aggregate into compact nodules within embryonic tissue (Hall and Miyake 1995). A 
portion of these cells differentiate into osteoprogenitor cells and then transform into 
osteoblasts, forming an ossification center. These osteoblasts synthesize a collagenous 
organic matrix (osteoid) which is then mineralized (Franz-Odendaal, Hall, and Witten 
2006). Woven bone tissue accumulates between embryonic blood vessels resulting in a 
network of trabeculae bone. On the external face of the woven bone, vascularized 
mesenchyme condenses and becomes the periosteum (Franz-Odendaal, Hall, and Witten 
2006).
Endochondral ossification entails the conversion of a cartilaginous template into 
bone, beginning during fetal development and continuing into early adulthood (Ortega, 
Behonick, and Werb 2004). Initially, embryonic mesenchymal stem cells condense and 
differentiate into chondroblasts that secrete a collagenous extracellular matrix, forming 
an avascular cartilaginous model of the bone. These cells calcify the matrix and then 
undergo programmed cell death (apoptosis), creating cavities within the bone (Hartmann 
2006). An outer periochondrium layer develops, composed of flattened densely packed 
mesenchymal cells that differentiate into osteoprogenitor cells (Hartmann 2006). Blood 
vessels invade the cartilaginous template, bringing in osteoclasts, hemopoietic cells and 
osteoprogenitor cells (Mackie et al. 2008). Osteoblasts, differentiated from 
osteoprogenitor cells, utilize the calcified matrix as a temple and subsequently replace the 
cartilage with bone (Garimella et al. 2004).
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1.2.4 Regulation of Osteoblastogenesis
Mesenchymal progenitor cells can differentiate into a number of cell types, 
including adipocytes, myoblasts, chondrocytes and osteoblasts (Bennett et al. 2005; Phan, 
Xu, and Zheng 2004). The process of osteoblastogenesis is regulated by a complex 
network of molecular signals and transcription factors, summarized in Figure 1.1.
1.2.4.1 Transcriptional Regulation of Osteoblastogenesis
By studying the skeletal phenotype in animals with targeted deletions and 
analyzing the transcriptional complexes formed during osteogenesis, a number of 
transcription factors involved in osteoblastogenesis have been identified (Ducy et al. 
1997; Luo et al. 1995). This includes runt-related transcription factor 2/core-binding 
factor alpha 1 (Runx2/Cbfal) and osterix (Osx), two transcription factors that play an 
essential role in inducing the differentiation of mesenchymal cells into cells of the 
osteoblast lineage. Targeted deletion of Runx2/Cbfal results in a cartilaginous skeleton 
and the complete absence of osteoblasts (Komori et al. 1997). Additional factors, such as 
the transcription factor osterix, have been shown to act along with Runx2/Cbfal to induce 
osteoblastogenesis (Harada and Rodan 2003).
1.2.4.2 Osteoblastogenesis Regulation by Hormones, Cytokines and Growth Factors
Several lines of evidence demonstrate that hormones, cytokines and growth 
factors influence numerous aspects of osteoblastic proliferation, differentiation, as well as 
activity and survival. Studies suggest that bone abnormalities may be related, at least in 
part, to altered osteoblast differentiation (a point at which bone formation can be 
regulated). This section reviews some the important hormones, cytokines and growth 























Figure 1.1 Regulation of Osteogenesis. Multipotent mesenchymal progenitor cells 
initially differentiate into preosteoblasts, a process requiring the expression of 
transcription factor Runx2/Cbfal. Osx acts downstream of Runx2 to induce 
preosteoblasts to differentiate into functional osteoblasts expressing high levels of 
osteoblast marker genes. Abbreviations: Runx2/Cbfal, runt-related transcription factor 
2; Osx, Osterix; Col-1, collagen 1; BMPs, bone morphogenetic proteins; TGFß, 
transforming growth factor beta.
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Bone Morphogenetic Proteins -  serine/threonine kinase receptor. In 1965, 
orthopaedic surgeon Dr. Marshall Urist discovered that demineralised bone matrix could 
induce bone formation via the release of stored protein he termed bone morphogenetic 
proteins (BMPs). Since then BMPs have been utilized as therapeutic agents in treatment 
of skeletal fractures and disease, and in oral and maxillofacial surgical procedures 
(Kamiya and Mishina 2011; Wozney and Rosen 1998).
BMPs belong to the larger transforming growth factor beta (TGF-P) superfamily 
of cytokines and induce differentiation and proliferation of numerous cell types, 
including osteoblasts (Zheng, Wood, and Papadimitriou 1992). BMPs elevate alkaline 
phosphatase, bone sialoprotein, osteopontin and osteocalcin levels, markers of osteoblast 
differentiation, in pre-osteoblastic cells lines (Yamaguchi et al. 1996; Yamaguchi, 
Komori, and Suda 2000). This data indicate that BMPs are inducers of osteoblasts 
differentiation.
Loss-of-function BMP-5 gene mutation results in murine short ear syndrome, 
characterized by a wide range of bone abnormalities (Feldman et al. 2007; Mikic et al. 
1995). BMP-7-deficient mice have skull, hind limb and rib cage skeletal defects (Luo et 
al. 1995). Taken together, these data demonstrate that BMPs are key regulators of bone 
formation.
Wnts. Wnt glycoproteins regulate a variety of cellular activities by binding to 
cell-surface Frizzled and LRP5/6 receptors. Canonical Wnt signaling increases levels of 
P-catenin, promoting transcription of target genes (Caetano-Lopes, Canhao, and Fonseca 
2007). Accumulation of P-catenin is essential for the differentiation of mature 
osteoblasts, but is not necessary the differentiation of osteoprogenitor cells to pre­
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osteoblasts (Glass et al. 2005; Hartmann 2006). WntlOb expression in mesenchymal 
progenitor cells in vitro induces expression of Runx2/Cbfa-1 and Osx transcription 
factors. Furthermore, WntlOb suppresses the adipogenic transcription factor PPARy 
(Albers et al. 2011). Taking together, these data indicate a key role for Wnt proteins as 
endogenous regulators of bone formation.
Parathyroid hormone -  GPCR. Parathyroid hormone (PTH) is secreted by 
chief cells of the parathyroid gland and acts to increase blood calcium levels. PTH and 
PTH-related peptide (PTHrP), structurally similar to PTH and originally discovered in 
malignancies, interact with common G protein-coupled receptors (GPCRs), termed 
PTH/PTHrP receptor (PTHR) (Chang et al. 2007; Falzon and Du 2000). PTH has also 
been shown to enhance activity of the osteoblastic transcription factor Runx2/Cbfal in 
mesenchymal cells, inducing osteoblastic commitment (Selvamurugan et al. 2000). Mice 
homozygous for PTHrP null mutation displayed lethal skeletal dysplasia with no 
apparent morphological abnormalities apparent in other tissues (Karaplis et al. 1994). 
Taken together, these studies provide evidence implicating a requirement for PTHrP in 
bone formation.
TGF-P -  serine/threonine kinase receptor. TGF-P synthesis and secretion by 
osteoblasts was first demonstrated through immunoprecipitation (Robey et al. 1987). 
1987). Latent TGF-P is stored in the bone matrix, later to be released in an active form by 
resorbing osteoclasts (Bonewald and Dallas 1994). Chemotactic activity of TGF-P was 
demonstrated with fetal rat calvarial and ROS 17/2.8 osteosarcoma cells (Pfeilschifier et 
al. 1990). TGF-P has been shown to repress transcriptional activity of Runx2/Cbfal and 
osteocalcin expression, demonstrating a regulatory role for TGF-P in osteoblast
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differentiation (Alliston et al. 2001).
Vitamin D -  nuclear receptor. 1,25-dihydroxyvitamin D3 (D3) is a steroid 
hormone that is involved in plasma mineral homeostasis and is essential in maintaining 
calcium and phosphate concentrations (Holick 1995; Kim 2011). Through the actions of 
UV B sunlight on 7-dehydrocholesterol in human skin, a biologically inactive pre­
vitamin D3 is produced. This inactive pre-vitamin D3 undergoes sequential 
hydroxylations in the liver and kidney to create the hormonally active form of vitamin D, 
1,25-dihydroxyvitamin D3 (Kim 2011). Vitamin D3 deficiency causes rickets and 
osteomalacia, characterized by inadequate bone mineralization, rib beading, scoliosis and 
frontal bossing (Kim 2011).
Vitamin D3 deficiency results in insufficient calcium-phosphate ion 
concentrations in the extracellular fluid required for osteoblast-mediated bone 
mineralization (Kim 2011). Furthermore, vitamin D3 inhibits proliferation, stimulates 
alkaline phosphatase, and modulates collagen type 1 synthesis in rat osteoblast cultures, 
demonstrating a regulatory role for vitamin D3 in osteoblast function (Owen et al. 1991).
Lysophosphatidic acid (LPA), a major serum lipid, has been shown to act 
synergistically with vitamin D3 in stimulating MG63 human osteoblast-like cell 
maturation (Gidley et al. 2006), suggesting LPA and vitamin D3 together play a key role 
in osteoblasts maturation.
1.2.5 Bone Remodeling
Bone remodelling involves the coordinated actions of osteoclasts and osteoblasts 
that combine to maintain skeletal integrity (Frost et al. 1998). Osteoclasts and osteoblasts 
together with their precursor cells are organized in specialized units termed basic
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multicellular units that are exclusively responsible for bone remodeling (Arvidson et al. 
2011; Frost et al. 1998) The remodeling cycle involves up to five sequential steps: 1) 
activation/initiation, 2) resorption, 3) reversal/ osteoprogenitor recruitment 4) osteoblast 
differentiation and 5) mineralization (Figure 1.2) (Kearns, Khosla, and Kostenuik 2008). 
Osteoclast precursors are recruited to a site of “activated” bone, where they fuse together 
to form multinucleated preosteoclasts, wherein various signaling molecules facilitate their 
maturity. Osteoclasts orchestrate the resorption phase where, upon completion they 
undergo apoptosis. The reversal phase is initiated by introduction of preosteoblasts. 
Osteoblasts synthesize new bone matrix (osteoid) and regulate its mineralization. 
Resorption is completed in 2-3 weeks, whereas new bone matrix formation and its 
mineralization take approximately three months. The replacement of new bone in the 
resorption pit is incomplete in many pathological conditions, resulting in a net loss of 
bone mass with each remodeling cycle (Kearns, Khosla, and Kostenuik 2008).
Osteoblasts are not only defined by their ability to synthesis, secrete and 
mineralize bone matrix, they are also required for osteoclast differentiation (Glass et al. 
2005). Osteoblasts secrete two main cytokines required for osteoclast differentiation: 
macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor- 
kB ligand (RANKL) (Glass et al. 2005). RANKL couples to its receptor RANK on pre­
osteoclasts, inducing differentiation, activation and survival. Notably, osteoclast 
precursors express RANK and recognize RANKL through cell-to-cell interaction with 
osteoblasts (Suda et al. 1999).
Some osteopetrotic mouse models have been shown to lack functional M-CSF 
protein required to stimulate osteoclast development (Felix, Cecchini, and Fleisch 1990).
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Figure 1.2 Schematic of Bone Remodeling. Osteoclast precursors are recruited to a site 
of "activated" bone, where they fuse together to form multinucleated osteoclasts, 
adhering firmly to the bone matrix. Osteoclasts Initiate the bone remodeling process by 
resorbing bone, creating a pit. Osteoclasts undergo apoptosis and osteoblasts 
precursors are attracted during the reversal phase. Pre-osteoblasts differentiate into 
mature osteoblasts which synthesize a collagenous organic matrix (osteoid), filling the 
resorption cavity. Osteoblasts express M-CSF, RANKL and/or OPG, regulating pre­
osteoclast and osteoclast activity. The same osteoid is then mineralized to complete the 
remodeling process. As bone mineralization continues osteoblasts are embedded in the 
matrix, becoming osteocytes that maintain contact with each other through their 
processes. Abbreviations: IGF, insulin-like growth factor; M-CSF, macrophage colony- 
stimulating factor; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-xB; 
RANKL, receptor activator of nuclear factor-xB. Figure adapted with permission from 
"Bone Remodeling Cycle" (University of Michigan).
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Furthermore, when anti-M-CSF antibody was added to a co-culture system of mouse 
osteoblastic cells and spleen cells, osteoclast-like multinucleated cells development was 
inhibited (Takada, Kouzmenko, and Kato 2009). Taken together, these data demonstrate 
that M-CSF is fundamental for the proliferation and maturation of osteoclasts.
Osteoblasts express a third gene that stimulates osteoclast differentiation, 
interleukin-6 (IL-6). IL-6 induces osteoclast differentiation from precursors and 
stimulates the activity of mature osteoclasts. For example, IL-6, produced by cytokine- 
stimulated MC3T3-E1 osteoblastic cells, increases osteoclast number three fold and 
induces bone resorption in calvaria cultures (Ishimi et al. 1990)
In addition to these positive regulators of osteoclast differentiation, osteoblasts 
express a cytokine that negatively regulates osteoclast differentiation. Osteoprotegerin 
(OPG) acts as a decoy receptor for RANKL, thus blocking the RANKL/RANK 
interaction and preventing osteoclast differentiation (Caetano-Lopes, Canhao, and 
Fonseca 2007; Kearns, Khosla, and Kostenuik 2008).
Osteoblasts synthesize and secrete cytokines and growth factors that are 
incorporated in the mineralized bone matrix and then released during the bone resorption 
phase of remodelling (Canalis, McCarthy, and Centrella 1991; Hauschka, Chen, and 
Mavrakos 1988). These factors are termed bone-derived growth factors and are similar, 
or identical to, insulin-like growth factors (IGFs). (Hauschka, Chen, and Mavrakos 1988).
Osteoblasts have been shown to possess type I receptors for IGF (Linkhart, 
Mohan, and Baylink 1996; Watson et al. 1995). Inhibition of endogenous IGF activity 
reduces proliferation and collagen synthesis in MC3T3-E1 osteoblast-like cells 
(Amamani et al. 1993). Furthermore, studies demonstrate that PTH stimulates IGF-I
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synthesis in ovariectomized PTH-treated rats, suggesting that IGF-I is a local mediator of 
PTH-induced bone formation (Watson et al. 1995).
1.3 G Protein-Coupled Receptor Signaling
1.3.1 G protein-coupled receptors
G protein-coupled receptors (GPCRs) play an essential role in transducing signals 
across the plasma membrane in all cell types. Also termed serpentine, heptahelical or 
seven transmembrane domain receptors, GPCRs share a common structure; extracellular 
N-terminus, seven transmembrane core, three extracellular and three cytosolic loops, and 
a cytosolic C-terminus. GPCRs transduce signals through heterotrimeric guanine 
nucleotide-binding proteins (G proteins); however alternate signaling pathways have 
been identified. Heterotrimeric G proteins are composed of a, p and y subunits, and 
belong to the GTPase group of enzymes. Cloning by homology has revealed that human 
G proteins derive from 35 genes, encoding 16 a subunits, five P and 14 y (Milligan and 
Kostenis 2006). The a subunit possesses high affinity for guanine nucleotides (GDP or 
GTP). In the absence of an agonist, the inactive Ga subunit is bound to GDP and binds 
tightly to the Py subunits. Ligand binding to the GPCR’s extracellular region results in an 
allosteric change in loops 3 and 6. The receptor then associates more efficiently with the 
Ga subunit and acts as a guanine nucleotide exchange factor (GEF), inducing the 
exchange of GDP for GTP, thereby activating Ga (Hepler and Gilman 1992). Activated a 
subunit dissociates from the Py subunits, which remain tightly linked as an undissociable 
dimer (Hepler 2003; Milligan and Kostenis 2006). Ga-GTP and Gpy subunits modulate 
the activity of downstream effector molecules independently or together (Hepler and
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Gilman 1992; Milligan and Kostenis 2006). The a subunit has intrinsic GTPase ability, 
hydrolyzing the terminal phosphate of bound GTP to GDP, promoting re-association of 
the a and Py subunits. Regulators of G protein signaling (RGS) proteins enhance the 
GTPase activity of the a subunit, limiting the lifetime of Ga-GTP and terminating 
signaling (Hepler 2003). There are four principal isoforms of a subunits, affording Ga 
multiple functions: Gs, Gi/0, Gq/n and G12/13 (Wettschureck and Offermanns 2005).
1.3.2 Gs Signaling
Researchers investigating actions of the endotoxin from the bacterium Vibrio 
cholera (cholera toxin, CTX) discovered the Gs isoform of G proteins. Application of 
CTX to cells induced sustained generation of 3’,5’-cyclic adenosine monophosphate 
(cAMP) (Gill and Meren 1978). Binding assays of [32P]NAD+, identified Gs as having an 
oligomeric structure with 45, 35 and 8-10 kDa proteins; subsequently named the a, P and 
y subunits respectively (Gilman 1984). Four Gs protein subtypes have been identified;
G(S), Gs(l), Gs(xl) 5 and G0if (Milligan and Kostenis 2006). Canonical Gs signaling 
pathways include enhanced adenylyl cyclase activity inducing cAMP production, as well 
as protein kinase A and phosphodiesterase activation (Neves, Ram, and Iyengar 2002).
1.3.3 Gj/0 Signaling
Studies investigating the mechanistic actions of pertussis toxin (PTX) uncovered 
the Ga protein isoform Gi/0. Whooping cough (pertussis) is caused by the Bordetella
pertussis secreted exotoxin. Purification of PTX substrate identified a 41 kDa protein that 
copurified with 35 and 8-10 kDa proteins, respectively termed a, P and y subunits 
(Bokoch et al. 1984). Seven Gj/0 G proteins are currently identified: G01, G02, Gji, G^,
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Gb, Gz, Gt and Ggust (Milligan and Kostenis 2006). Multiple hormones and 
neurotransmitters, including dopamine, serotonin, acetylcholine and epinephrine, use the 
Gj/o pathway to elicit physiological responses (Neves, Ram, and Iyengar 2002). Members 
of the Gj family were originally identified by the capacity of Gai to ‘inhibit’ adenylyl 
cyclase and decrease activity of Ca channels (Milligan and Kostenis 2006; Neves, Ram, 
and Iyengar 2002). G0 was identified more recently -  ‘o’ denotes ‘other’.
1.3.4 Gq/n Signaling
CTX and PTX were found not to inhibit the receptor-mediated production of the 
intracellular messenger inositol trisphosphate (IP3) and subsequent release of Ca from 
intracellular stores, indicating the involvement of a novel G protein (Milligan and 
Kostenis 2006). Subsequent research identified two 42 kDa alpha subunits, 88% identical 
in amino acid sequence, termed Gq and Gn (Strathmann and Simon 1990). Canonical
signaling by involves Gq/n stimulation of phospholipase Cp (PLCP) to generate IP3 and 
diacylglycérol from phosphatidylinositol bisphosphate. IP3 triggers the release of calcium 
from the endoplasmic reticulum, while diacylglycérol concurrently recruits protein kinase 
C to the membrane activating it (Mizuno and Itoh 2009; Rhee 2001). The Gq family 
includes: Gq, Gu, G14 and G15/16 (Malbon 2005). In addition, Gq/n regulates the actin 
cytoskeleton and gene transcription through the Rho guanine nucleotide exchange factor, 
p63RhoGEF. (Mizuno and Itoh 2009).
1.3.5 G12/13 Signaling
G12/13 proteins were identified through amino acid sequence similarity to known 
Ga proteins (Neves, Ram, and Iyengar 2002; Yamazaki et al. 2005). These G proteins
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stimulate DNA synthesis, proliferation and promote focal adhesions and stress fibre 
formation associated with changes in cell morphology (Riobo and Manning 2005). G12/13 
functions through multiple effectors including pll5-Rho guanine nucleotide-exchange 
factor, leukemia-associated Rho GEF and cell adhesion molecules, (Riobo and Manning 
2005). Evidence suggests that there is coordinated signaling of receptors to G12/13 and Gq 
for platelet activation and smooth muscle contraction (Riobo and Manning 2005).
1.3.6 py Complex Signaling
The py complex, initially regarded as a passive partner of Ga, is now known for 
its ability to interact with multiple downstream effectors. Evidence that Gpy could control 
effectors emerged when investigations showed that purified Gpy could activate cardiac K+ 
(GIRK 1, 2, 4) channels (Kim et al. 1989). Furthermore, studies on Gaj proteins in
leucocytes treated with PTX, showed receptor mediated PLCP activity, indicating the 
existence of Py complex-interacting proteins (Milligan and Kostenis 2006). The evidence 
that Gpy interacts directly with downstream effectors will aid in our understanding of G- 
protein signal transduction.
1.4 Lysophosphatidic Acid
Lysophosphatidic acid (LPA) is a simple, naturally occurring, lysophospholipid 
found to be an intermediate in phospholipid metabolism. LPA is comprised of a single 
fatty acyl chain, a glycerol backbone and a phosphate group (Aoki 2004; Mills and 
Moolenaar 2003). LPA is derived from precursor membrane phospholipids through the 
activity of several enzymes. Multiple LPA isoforms can be generated depending on the
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predecessor phospholipids and activity of the enzyme. The term LPA commonly refers to 
the isoform l-acyl-2-hydroxy-sn-glycero-3-phosphate (Choi et al. 2010; Noguchi et al. 
2009). Naturally occurring LPA analogues interact with several cell surface GPCRs and 
nuclear hormone receptor (PPARy). Members of the LPA family regulate numerous cell 
functions and have been shown to play an essential role in many pathological and 
physiological processes including embryonic development and cancer progression. The 
major physiological and pathophysiological effects of LPA are summarized in Table 1.1.
1.4.1 Lysophosphatidic Acid Synthesis and Degradation
LPA is synthesized by a variety of cell types including osteoblasts, lymphocytes, 
adipocytes, platelets, chondrocytes, neutrophils, post-mitotic cortical neurons and tumor 
cells. LPA is an abundant constituent of serum, bound to albumin, presented at 
concentrations of 1-5 pM, with elevated concentrations (up to 25 pM) during wound 
healing, inflammation and tumorigenesis, where it is released by activated platelets and 
mast cells (Bese, Barbaras et al. 2010). Plasma LPA concentration in healthy individuals 
is ~ 0.085 pM (Hosogaya, Yatomi et al. 2008), whereas ovarian cancer patients were 
reported to have significantly higher plasma LPA concentrations of a mean of 8.6 pM. 
This finding suggests a correlation between plasma LPA concentration and cancer 
progression (Pua, Wang, and Fishman 2009).
Synthesis of LPA can occur through at least two major pathways summarized in 
Figure 1.3. Fatty acids can be linked at the sn-1 position (saturated) or sn-2 position 
(unsaturated), thus phospholipase Ai (PLAi) or phospholipase A2 (PLA2) could be 
involved in the synthesis of LPA. In the first pathway lysophospholipids are generated 
from the actions of PLAi or PLA2 on phospholipids. LPA (l-acyl-2-LPA or 2-
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Table 1.1 Major Biological Effects of LPA
Effect Cell Type
Cell Proliferation and survival Multiple cell types, normal and 
transformed
Cell migration (random and directed) and invasion Multiple cell types, normal and 
transformed
Cell contraction Smooth muscle cells 
Myofibroblasts
Cell clustering (N-cadherin-mediated) Schwann cells
Tumor progression Carcinoma 
Hepatoma 
T-lymphoma cells 
Breast and Ovarian cancers
Wound healing in vivo Skin
Intestinal epithelium
Platelet activation and aggregration 
Platelet-monocyte aggregation
Whole blood, LPA in atherosclerotic 
plaques; synergy with ADP
Neurite retraction Neuroblastoma cells
Collapse, turning of growth cones Primary neurons 
Cortical neruoblasts 
Xenopus retinal growth cones 
Xenopus spinal neurons 
Astrocytes
Inhibition/reversal of differentiation Neuroblastoma 
Glioma cells
Vascular smooth muscle cells
Membrane depolarization (chloride-mediated) Neuronal cells 
Fibroblasts
Increased endothelial permeability Brain capillary endothelial cells
Cytokine production Fibroblasts, astrocytes, leukocytes, 
epithelial and endothelial cells, 
carcinoma cells
Inhibition/reversal of differentiation Vascular smooth muscle cells 
Pre-adipocytes
Demyelination of the dorsal root ex vivo Myelinating Schwann cells
Table modified with permission from "Regulation and biological activities of the 
autotaxin-LPA axis" (van Meeteren et al., Prog Lipid Res 46:145-160, 2007).
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Figure 1.3 Schematic Illustrating Two Pathways of Lysophosphatidic Acid (LPA) 
Synthesis. A) Lysophosphospholipids (LPLs) are generated from the actions of PLA1 or 
PLA2 on phospholipids (PLs). LPA (l-acy-2-LPA or 2-acyl-l-LPA) is then produced from 
the LPLs by the plasma enzyme autotoxin (ATX/lysoPLD). B) Phosphatidic acid (PA) is 
first generated from phospholipids (PLs) by the actions of phospholipase D (PLD) and 
then deacylated by PLAi or PLA2 to generate LPA (l-acy-2-LPA or 2-acyl-l-LPA) 
Abbreviations: ATX/lysoPLD, autotaxin/lysophospholipase D; PLAi, phospholipase Ai; 
PLA2, phospholipase A2; PLD, phospholipase. Figures adapted with permission from 
"Mechanisms of lysophosphatidic acid production" (Aoki 2004).
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autotaxin (ATX) (Aoki 2004). In the second pathway, phosphatidic acid (PA) is first 
generated from phospholipids by phospholipase D and then deacylated by PLAi or PLA2 
to generate LPA (l-acyl-2-LPA or 2-acyl-1-LPA) (Aoki 2004). LPA is also produced 
from monoacylglycerol by the actions of MAG kinase (Gardell, Dubin, and Chun 2006).
Extracellular LPA is degraded by at least three lipid phosphate phosphatases 
and/or LPA acyltransferase (Gardell, Dubin, and Chun 2006). LPA can be converted to 
phosphatidic acid by LPA acyltransferase, an enzyme found in the plasma membrane 
(Bursten et al. 1991). Via the actions of lipid phosphate phosphatases, LPA is converted 
to monoacylglycerol, (Brindley and Pilquil 2009).
1.4.2 Lysophosphatidic Acid Receptors
The discovery and functional identification of plasma membrane LPA receptors 
was key to understanding the mechanisms of LPA-induced signaling. The existence of 
multiple LPA receptor subtypes, unique tissue distribution and effector pathways can 
account for the wide variety of LPA-regulated biological processes. LPA signaling is 
mediated by at least six identified GPCRs termed LPA1.6. LPA receptors couple to 
multiple G proteins, including Gi/0, Gs, Gq/n and G12/13. Recent evidence has suggests 
three additional, poorly characterized, GPCRs; P2Y5, P2Y10 and GPR35, responsive to 
LPA, along with a nuclear transcription factor peroxisome proliferator-activated receptor 
gamma (PPARy) (Ishii et al. 2004; Meyer zu Heringdorf and Jakobs 2007; Noguchi et al. 
2009). We investigated the expression o f LPA ¡.ÿ in cells o f the osteoblast lineage.
Classification and Properties of Lysophosphatidic Acid Receptors. LPA 
receptors can be classified into two subgroups: an endothelial differentiation gene (Edg) 
and a P2Y (purinergic) subgroup. The best characterized LPA receptors are the Edg
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family of LPA receptors: LPA 1,2,3 (Edg2,4,7) sharing -50% amino acid sequence 
homology.
LPAi. LPAi (Edg2) was the first high-affinity LPA receptor to be identified. It 
was termed ventricular zone gene-1 ('vzg-1) because of its enriched expression in the 
neurogenic ventricular zone of the embryonic cortex (Contos et al. 2000; Liu et al. 2009). 
LPAi is ubiquitously expressed, with elevated expression in brain, heart, prostate, testis, 
ovary, skeletal muscle and small intestine (An et al. 1997; Choi et al. 2010).
In general, LPAi couples with Gi/0, Gq/n, and G12/13 (Liu et al. 2009). LPA- 
activation of these proteins induces multiple cellular responses, such as; adenylyl cyclase 
inhibition, PLC activation, Ca mobilization, AKT activation, Rho and mitogen 
activated protein kinase activation (Liu et al. 2009).
LPAi has been implicated in the migration and invasion of tumor cells. Silencing 
LPAi expression in ovarian and breast cancer cells blocked the synthesis of tumor- 
derived cytokines that activate osteoclast-mediated bone resorption and significantly 
reduces the progression of osteolytic bone metastases (Boucharaba et al. 2004).
A recent study revealed LPAi1' mice bone phenotype showed low mass, 
craniofacial deformities and ribcage abnormalities. Furthermore, bone marrow 
mesenchymal progenitors from these mice displayed decreased osteoblastic 
differentiation (Gennero et al. 2011). This study confirms our findings that LPAi plays an 
important role in osteoblast differentiation, suggesting LPAi expression may influence 
bone development.
LPA2. LPA2(Edg4) has distinct tissue distribution from that of LPAi; transcripts 
encoding LPA2 were revealed in peripheral blood leukocytes, as well as spleen, thymus,
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prostate, testis and pancreas (An et al. 1997; Choi et al. 2010). LPA2 interacts with Gi/0, 
Gq/n and G12/13 proteins (Ishii et al. 2004).
LPA2'1' mice exhibited no physiological abnormalities, however there was 
elevated incidence of frontal hematoma in LPAfl'LPA2~1' compared to the single LPAf1' 
mice (Contos et al. 2000).
LPA3. Transcripts encoding LPA3 (Edg7) were found in human heart, pancreas, 
testis, prostate, and ovary (Bandoh et al. 1999). LPA3 protein is 53.7 and 48.8% identical 
in amino acid sequence to human LPAi and LPA2 receptors, respectively (Bandoh et al.
*yi
1999). LPA3 couples to Gq and PLC to promote release of Ca from intracellular stores, 
as well as elevating cAMP through a PTX-insensitive pathway (Bandoh et al. 1999). 
Studies have identified LPA3 receptor-mediated signalling involvement in early 
pregnancy.
Elevated LPA3 mRNA expression within the uterus was discovered during early 
pregnancy and LPA3 stimulation promoted uterine contraction around E3.5, a mechanism 
essential for embryo spacing in mice (Ziecik, Waclawik, and Bogacki 2008). This data 
indicate that LPA3 plays an integral role in reproductive physiology, implicating this 
receptor as a target for assisted reproductive technologies.
LPA4. LPA4 (P2Y9/GPR23) shares only 20-24% amino acid identity with the 
three Edg LPA receptors, and phylogenetic analysis revealed that it is more closely 
related to P2Y nucleotide receptors (Oh et al. 2008). Radioligand assay showed binding 
of [3H]-LPA on rat hepatoma LPA receptor-null RH7777 cells stably expressing LPA4 
indicating that P2Y9/GPR23 is the fourth LPA receptor (Noguchi et al. 2009).
Human LPA4 is ubiquitously expressed in human tissue and dominates in the
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ovary (Noguchi et al. 2009). Moreover, human LPA4 interacts with all four G protein 
subtypes (Ishii et al. 2004). LPA4 stimulation includes: stress fiber formation through 
Gai2/i3-mediated Rho activation; Gq and PTX-sensitive [Ca ], mobilization; and Gs 
mediated elevation of cAMP (Yanagida et al. 2009).
LPA4'1' mice display no major abnormalities; however, embryonic fibroblasts 
from LPA4 ’ mice showed enhanced migration, consistent with negative regulation of the 
PI3K pathway by LPA (Lee et al. 2008).
LPA5. LPA5, formerly known as GPR92, has approximately 35% sequence 
identity with LPA4. The same experiments that were used to identify LPA1-4, showed 
LPA5 expression in rat B103 neuroblastoma and hepatoma LPA receptor-null RH7777 
cells (Lee et al. 2006). Transcripts encoding LPA5 were found in murine embryonic 
brain, small intestine, spleen and thymus tissues cells (Lee et al. 2006). LPA5 interacts 
with Gq, Gs and G12/13 to activate PLC, increase [Ca2+]j, elevate cAMP and induce 
cytoskeletal rearrangements mediated by RhoA/Rho-associated protein kinase, 
respectively.
LPA5 is the most abundant LPA receptor in human platelets and is thought to play 
a role in platelet activation (Khandoga et al. 2008), suggesting LPA5 may be a target for 
anti-thrombotic therapy.
LPA6. The orphan GPCR P2Y5 was identified as an LPA receptor in 2009 
(Yanagida et al. 2009). P2Y5 was thought to be a purinergic receptor based on the degree 
of sequence identity shared with P2Y receptor family members (Webb, Kaplan et al. 
1996). However, further studies determined that nucleotide treatment of P2Y5 stably 
expressed cells had no effect on inositol phosphate or cAMP concentrations, indicating
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the P2Y5 is not a member of the P2Y receptor family (Li et al. 1997).
2
Radioligand assay shows binding of [ H]-LPA on rat hepatoma LPA receptor-null 
RH7777 cells stably expressing P2Y5. LPA is capable of evoking membrane blebbing 
and neurite retraction in these cells, respectively, effects that were attenuated by Rho- 
associated kinase inhibitor Y-27632 (Li et al. 1997). Furthermore, [35S]GTPyS combined 
to G13, indicating that these alterations in cellular morphology are mediated via P2Y5 -  
G12/13 -  Rho-associated kinase pathway (Yanagida et al. 2009).
Recent investigations indicate that P2Y5 is essential for the maintenance of hair 
growth. P2Y5 mutations are responsible for the autosomal recessive form of 
hypotrichosis, a condition characterized by body hair that is present at birth, is basically 
lost (Pasternack et al. 2008).
PPARy. Peroxisome proliferator-activated receptor gamma (PPARy) is a ligand- 
activated transcription factor that induces adipogenesis and inhibits osteoblastogenesis. 
Recently, studies have demonstrated that inducers of osteoblastogenesis impede the 
transactivation ability of PPARy during osteoblastogenesis (Takada, Kouzmenko, and 
Kato 2009). PPARy has been identified as an intracellular receptor for the lipid signaling 
molecule lysophosphatidic acid (LPA) (Maeyama, Emi, and Tachibana 2005). In the 
mouse preadipose cell line 3T3F442A, LPA inhibits PPARy expression, reduces the 
expression of adipocyte markers and attenuates adipogenesis, suggesting LPA may play a 
role in osteoblastogenesis (Pittenger et al. 1999).
LPA receptors, gene names, agonists/antagonists and associated G proteins are
summarized in Table 1.2.
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Table 1.2 LPA Receptors
R e ce p to r S y n o n y m s G e n e A g o n is t A n ta g o n ist G C e llu la r Physiological/
P ro te in R e sp o n se Pathological
Function
LPAi V Z G -1 L P A R l/ c h r 9 LPA V P C 3 2 1 8 3 Gi/o P ro life ra tio n Brain
ED G 2 V zg -1 V P C 1 2 4 4 9 Gq/11 S tre ss  f ib re s d e v e lo p m e n t,
R e c l.3 L P A a i  UPa i ) K Ü 6 4 2 5 G 12/13 R e tra ctio n C a n ce r
G P R 2 6 (h u m a n ) M igra tio n m é ta sta sé s,
G P C R 2 L p a r l/ c h r 4 C a 2+ P u lm o n a ry  &
(m o u se ) m o b ilizatio n renal f ib ro sis
l p a 2 ED G 4 L P A R 2 / c h r l9 LPA A m g e n 2 5 Gj/o T u m o r V a scu la r
L P A a i  UPA2) G q /n m igratio n in ju ry
(h u m a n )
L p a r2 / c h r8
(m o u se )
G 12/13 R o u n d in g
l p a 3 ED G 7 L P A R 3 / c h r l LPA V P C 3 2 1 8 3 Gi/o P ro life ra tio n Em b ryo
l p A a3 Up  A3) O M P T V P C 1 2 4 4 9 G q / ll Su rv iv a l im p lan tatio n
(h u m a n ) T 13 K U 6 4 2 5 C a 2+ & sp a cin g
L p a r3 / c h r3
(m o u se )
m o b iliza tio n
LPA 4 G P R 23 L P A R 4 / c h rX LPA N/A Gi/o A d h e s io n C a n ce r
P2Y9 (h u m a n ) G q / ll M igra tio n m é ta sta sé s
P2Y 5-like L p a r4 / c h rX Gl2/13 S tre ss  fib re s
(m o u se ) G s C a 2+
m o b iliza tio n
LPA S G P R 92 L P A R 5 / c h r l2 LPA N/A G q /n R e tra ctio n P la te le t -
G P R 93 (h u m a n )
L p a r5 / c h r6
(m o u se )
G 12/13 S tre ss  fib re s a ctiva tio n
l p a 6 P2Y5 P 2 Y R 5 / c h rX N/A Gq B le b b in g H air g ro w th
(h u m a n )
P 2 y r 5 / c h r l4
(m o u se )
R e tra ctio n
PPA R y P P A R A d ip o g e n e sis
e le m e n ts
Table modified with permission from "Lysophosphatidic acid (LPA) and its receptors" 
(Noguchi et al. 2009). See text for references.
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1.4.3 LPA Receptor Expression in Osteoblasts
Primary osteoblasts and osteoblast-like cells lines have been shown to express
• • 'X'y •LPA receptors. Rat osteosarcoma cell line, UMR-106, derived from a P-induced 
(radiophosphorous) osteosarcoma rats were utilized in this study. UMR-106 cells have 
been shown to express LPAi (Edg2), (Grey et al. 2001). Murine MC3T3-E1 osteoblastic 
cell line, also utilized in this study, express LPA^, with relative mRNA abundance of 
LPAi > LPA4 > LPA2»  LPA3, with LPA3 transcripts barely detectable by real-time RT- 
PCR (Masiello et al. 2006). RT-PCR has revealed expression of LPAi in primary rat 
osteoblasts (Grey et al. 2001) and both LPAi and LPA2 in primary human osteoblastic 
cells (Dziak et al. 2003). Presence of functional LPA receptors in osteoblasts suggests 
LPA functions as a signaling molecule to mediate osteoblast function. However, the 
signaling pathways that are activated by these receptors in osteoblasts are not fully 
understood.
1.4.4 LPA Receptor Agonists and Antagonists
The development of LPA receptor agonists and antagonists has been fundamental 
in elucidating the roles of LPA signaling in bone (Table 1.2). Most compounds for LPA 
receptors target LPAi.3 (Choi et al. 2010).
Dual LPA1/3 antagonists have been developed including Ki 16425 and VPC32183 
utilized in this study (Parrill 2011), as well as VPC12249. VPC32183 and VPC12249 
compounds are LPA analogs, Ki 16425 (chemically dissimilar to LPA) was isolated from 
a compound library (Heasley et al. 2004; Noguchi et al. 2009). VPC 12249 is a low 
affinity antagonist that is somewhat selective for LPA1/3.
Ki 16425 has been utilized in a number of different cell culture experiments to
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inhibit LPA-mediated processes such as Ca mobilization, migration and morphological 
changes (Noguchi et al. 2009; Ohta et al. 2003). In addition, Ki 16425 administration 
reduces the metastatic potential of breast cancer in a xenograft tumor model (Boucharaba 
et al. 2004). Kil6425 has recently been licensed by Debiopharm Group (Switzerland) 
under the name “Debio 0719” and is in preclinical development as an antitumor drug 
(Noguchi et al. 2009; Ohta et al. 2003). It has been observed that Ki 16425 exhibits partial 
PPARy-agonist activity at concentrations higher than 10 pM, indicating that some LPA 
receptor-independent effects of Ki 16425 cannot be disregarded (Durgam et al. 2005).
T13 and 1-oleoyl-l-O-methyl-rac-glycerophosphothionate (OMPT) are selective 
LPA3 agonists (Noguchi et al. 2009). OMPT, a thiophosphate derivative of LPA, has 
been employed in vivo to determine LPA3 involvement in renal ischemia-reperfusion 
injury (Okusa et al. 2003). T13, an LPA analog with carbohydrate scaffold, has been 
implemented in explant cultures to investigate the involvement of LPA3 in uterine 
contraction and embryo spacing (Tamaruya et al. 2004).
Numerous reports indicate that LPA receptor agonist and antagonist vary in 
selectivity and potency. Caution is needed when interpreting data generated with partially 
validated compounds, for variables such as compound half-life, receptor occupancy and 
off-target activities should be considered (Noguchi et al. 2009).
1.5 Lysophosphatidic Acid, Bone Metabolism and Osteoblasts
LPA been shown to regulate diverse cellular functions affecting both 
physiological and pathophysiological processes in bone. However, the mechanism by 
which LPA regulates these processes remains unclear.
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1.5.1 LPA Receptor Knockout Mice
Insights into the role of LPA receptors in bone development has been acquired from 
LPA receptor gene knockout (KO) mice. LPA/ deletion resulted in ~ 50% neonatal 
lethality, 30% reduction in overall size, impaired suckling ability and craniofacial 
deformities such as shorter snouts and widely spaced eyes (Contos et al. 2000). These 
data indicate a link between LPAi receptor expression and embryonic development and 
bone formation.
A recently published study described the bone phenotype of LPA f 1' mice was 
described (Gennero et al. 2011). These mice possessed the previously described 
craniofacial deformities as well as vertebral calcification, thoracic spine closure, stemo- 
distal rib fusion and shorter, crooked and thicker segments of the sternum. RT-PCR 
analysis showed decreased osteoblast differentiation markers in the radius and femur of 
these mice; however, Runx2/Cbfal transcription factor, required for initial osteoblast 
differentiation, was unchanged (Gennero et al. 2011).
LPAi1' mouse models did not display any marked phenotypic abnormalities (Contos 
et al. 2000). LPAf1'LPAi1' double KO mice displayed ho additional phenotypic 
abnormalities compared to LPA}'1' mice, except for the incidence of perinatal frontal 
hematoma (Contos et al. 2000). This study indicates that LPA2 is not essential for normal 
mouse skeletal development (Contos et al. 2000).
LPA 3-deficient mice have delayed uterine implantation, prolonged pregnancy and 
reduced litter size (Ye et al. 2005). Furthermore, cyclooxygenase-2, an enzyme 
demonstrated to influence implantation, was down-regulated in these mice. These data 
indicate the involvement of LPA3-mediated LPA signaling in implantation and embryo
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spacing in mice.
LPA ¿-deficient mice showed increased trabecular bone volume, number and thickness 
(Liu et al. 2010). These findings were consistent with the ability of LPA4 to inhibit the 
osteoblastic differentiation of a genetically modified mesenchymal stem cell line in vitro. 
Taken together, these studies indicate that LPA receptor signaling may play a role in 
normal osteoblastic differentiation and skeletal development.
1.5.2 Role of LPA in Breast Cancer Metastasis to Bone
LPA and its receptors are overexpressed in a variety of human cancers suggesting 
LPA synthesis and signaling may play a role in cancer progression (Liu et al. 2009). It 
has been suggested that platelet-derived LPA promotes progression of osteolytic bone 
metastases of breast cancer cells (David et al. 2010). Metastatic cancer cells secrete 
cytokine and paracrine factors, (IL-6, -8 and PTHrP), that stimulate osteoclast-mediated 
bone resorption resulting in osteolysis and subsequent cancer metastases (Mundy 2002). 
Silencing LPAi in cancer cells blocked tumor-derived cytokine production, significantly 
reducing progression of osteolytic bone metastases, implying a role for LPA in cancer 
progression (Boucharaba et al. 2004).
Breast cancer cell autotaxin expression influences osteolytic metastasis via LPA- 
dependent activation of osteoclast-mediated bone resorption (David et al. 2010). The 
specific analogue inhibitor of autotaxin (VPC8a202) blocks the autotaxin-dependent 
increase in osteoclastogenesis in vitro from OFI male mouse bone marrow cells treated 
with M-CSF and RANKL, suggesting that autotaxin-generated extracellular LPA may 
control osteoclastogenesis (David et al. 2010; Gidley et al. 2006). Furthermore, lipid- 
depleted serum was not able to support M-CSF/RANKL induced osteoclastogenesis, an
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effect that was rescued by the addition of LPA (1 pM). Taken together, these data suggest 
that LPA synthesis and LPAi expression in tumor cells may be a promising therapeutic 
target for cancer métastasés to bone.
1.5.3 LPA and Osteoblasts
The first evidence, to our knowledge, that LPA affects osteoblast-like cells was 
obtained by Verheijen in 1995, who showed that LPA induced MAP kinase activation in 
UMR-106 osteosarcoma cells (Verheijen and Defize 1995). Since that time, LPA has 
been demonstrated to elicit a number of responses in osteoblasts; however, the 
mechanisms underlying these responses remain poorly understood. Cellular responses in 
osteoblasts elicited by LPA are reviewed below.
Osteoblast Differentiation. Osteoblast differentiation is mediated, in part, by 
vitamin D3 interaction with other growth factors. In human MG-63 osteosarcoma cells 
cultures, application of LPA1/3 inhibitor Ki 16425 inhibited cell differentiation, alkaline 
phosphatase and osteocalcin activity in response to vitamin D3 (100 nM) and LPA (20 
pM) (Gidley et al. 2006). The authors show that vitamin D3 and LPA act together to 
promote osteoblast differentiation.
Bone marrow mesenchymal stem cells from LPAi1' mice displayed decreased 
proliferation, differentiation and mineralization in vitro compared to cells from wild type 
mice (Gennero et al. 2011); however, indirect effects of loss of LPAi cannot be excluded. 
The findings of Gennero and coworkers are in keeping with previous reports from our lab 
demonstrating that VPC32183 abolished the effects of BzATP-enhanced mineralization 
in rat calvarial cultures, indicating that BzATP-induced osteogenesis is dependent on 
pathways downstream of LPA receptors (Panupinthu et al. 2008).
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Human mesenchymal stem cells (hMSCs) are multipotent cells that can give rise 
in vitro to osteoblasts, adipocytes or chondrocytes depending on the culture conditions 
(Kim et al. 1989). These cells undergo senescence resulting in impaired differentiation 
and growth arrest. To overcome senescence, Simonsen et al. 2002 overexpressed 
recombinant human telomerase (TERT), resulting in hMSC-TERT cells that retain stem 
cell phenotype and have an extended life span of -400 population doublings (Abdallah et 
al. 2005). LPA has been shown to induce osteoblastic differentiation hMSC-TERT cells, 
an effect which was blocked by Ki 16425 (Liu et al. 2010). Furthermore, LPA had no 
effect on hMSC-TERT proliferation which is in contrast with other cell types.
These studies demonstrate that LPA induces osteogenic differentiation on 
osteoblast-like cell lines and genetically modified cells. Our studies investigated the 
osteogenic effects of LPA in primary osteoblasts.
Osteoblast Morphology. Cell maturation is often accompanied by morphological 
changes, including tension-dependent changes in the actin cytoskeleton (Gidley et al. 
2006; Huang and Ingber 2000). Vitamin D3 and LPA co-stimulation generated actin 
stress fibres and elevations of alkaline phosphatase in human osteosarcoma MG63 cells, 
an effect that was attenuated by the Rho-associated kinase inhibitor Y-27632, indicating 
that LPA-induced cytoskeletal changes are associated with osteoblast differentiation 
(Gidley et al. 2006).
Membrane blebs are spherical protrusion of the plasma membrane traditionally 
viewed as a sign of apoptosis. Blebbing is increasingly emerging as a dynamic feature of 
cell spreading, mitosis and migration. LPA induces dynamic membrane blebbing in 
murine calvarial osteoblast cultures, an effect that was abolished by VPC-32183 and Y-
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27632 suggests the involvement of LPA receptors and Rho-associated kinase (Panupinthu 
et al. 2007). These data suggest a role for LPA for membrane blebbing in osteoblasts; 
however, the signaling pathways and mechanisms mediating this effect are unclear and 
were investigated in this study.
Osteoblast Survival. Studies have demonstrated that LPA rescues serum- 
deprived osteoblasts from apoptosis. LPA decreased apoptosis, induced by serum 
withdrawal, by ~ 50% in primary rat osteoblast and SaOS-2 osteosarcoma cell cultures 
(Caverzasio et al. 2000; Dziak et al. 2003; Grey et al. 2001). Furthermore, these LPA- 
induced anti-apoptotic effects were blocked by PTX and by the PI3K inhibitors 
wortmannin and LY294002, implicating a role for Gi/0 proteins and PI3K in LPA-induced 
osteoblast survival (Grey et al. 2001). However, the signaling pathways mediating these 
are effects are not clearly understood and further investigations are required.
Mitogenic Effect of LPA on Osteoblasts. LPA has emerged as a bioactive 
compound that exerts mitogenic effects in many cell types, including osteoblasts. LPA 
induces an increase in DNA synthesis and cell number in primary cultures of human and 
rat osteoblasts as well as several osteoblast-like cell lines, MC3T3-E1, UMR-106, G292 
and MG63 (Caverzasio et al. 2000; Dziak et al. 2003; Grey et al. 2001). PTX attenuated 
LPA-induced DNA synthesis by ~ 71%, suggesting Gi/0 proteins mediate, at least in part, 
the proliferative effect of LPA on osteoblasts (Grey et al. 2001). Furthermore, calphostin 
C (a selective PKC inhibitor) blocked LPA-induced mitogenesis in these cells, indicating 
the mitogenic effects of LPA in osteoblastic cells involve PKC (Grey et al. 2001). 
Evidence from these studies suggests that LPA acts as mitogen in osteoblasts, however, 
further investigation is required to elucidate the mechanism underlying these effects.
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LPA and [Ca2+]t in Osteoblasts. Recent studies aim to elucidate the signal 
transduction pathways induced by LPA receptor stimulation in osteoblasts, in particular 
the mobilization of Ca2+. Ca2+ is a ubiquitous intracellular second messenger responsible 
for regulating numerous cellular processes such as mitosis, gene transcription and 
neuronal transmission. In most cells, basal [Ca ]i is ~ 100 nM, but can rise to 500 - 1,000 
nM upon activation.
Although several studies have examined LPA-induced Ca signaling in various 
osteoblast-like cell lines, little is known about the underlying mechanisms in primary 
osteoblast cell culture systems. In this regard, LPA was demonstrated to elevate [Ca ]j in 
hMSC-TERT cells (a genetically modified cell line), effects that were attenuated by the 
LPA1/3 antagonist Ki 16425 (Liu et al. 2010). These cells have not obtained an osteoblast 
phenotype; thus, this data may not correlate with the effects of LPA on primary 
osteoblasts. LPA (5 pM) elicited a rise in [Ca ]; in SaM-1 human osteoblastic cells (Aki 
et al. 2008), which was inhibited by 2-APB (IP3 receptor blocker) and Kil6425. These 
data suggest that LPA-induced [Ca2+]j occurs through LPA1/3 or activation of IP3 
pathways. However, concentrations of the LPA1/3 antagonist Kil6425 greater than 10 
pM has been shown to exhibits partial PPARy-agonism, indicating that some LPA 
receptor-independent effects of Ki 16425 cannot be disregarded (Durgam, Virag et al. 
2005). Furthermore, 2-aminoethoxy-diphenylborate (2-APB) has been reported to display 
nonspecific actions and the fact that its principal antagonistic effect is on Ca entry 
rather than Ca2+ release, this compound may not have the utility first suggested (Bootman
et al. 2002).
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Previous investigations have also suggested a role for LPA in Ca signaling in 
the MC3T3-E1 osteoblastic cell line. LPA-induce rise in [Ca2+]jin MC3T3-E1 cells was 
attenuated by BAPTA-AM and Kil6425 (Waters et al. 2007). Taken alone, this data 
does not clearly indicate the source of calcium. Further investigation is required to 
elucidate the signaling pathways involved in LPA-induced Ca in authentic osteoblasts. 
Single primary rat osteoblast pressure ejection of LPA (10 pM) was shown to elicit a rise 
in [Ca ]; (Panupinthu, Zhao et al. 2007), however, no further studies were completed to 
investigate the pathways involved in LPA signaling in primary osteoblasts. Clearly, there 
is a need to examine the mechanisms underlying LPA-induced Ca signaling in primary 
osteoblast cells.
In primary rat osteoblasts, LPA induced the phosphorylation of extracellular 
signal-regulated kinase (ERK) (Grey et al. 2001). This effect was blocked by the calcium 
chelator EGTA in the extracellular medium. In contrast, LPA-induced phosphorylation of 
ERK 1/2 was not blocked by the intracellular calcium-chelating agent BAPTA or the 
SERCA blocker thapsigargin (Grey et al. 2001). These data are consistent with LPA 
inducing influx of calcium from the extracellular fluid, which in turn is required for ERK 
phosphorylation.
Despite the importance of Ca as a second messenger, its transport, signaling, 
and role in regulating gene expression in osteoblasts remains poorly understood. 
Understanding the role that Ca plays in mediating the effects of LPA on authentic 
osteoblasts will further our knowledge of osteoblast differentiation, growth and function.
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1.6 Rationale, Objectives and Hypothesis of Research
1.6.1 Role of LPA in [Ca2+]j Signaling and Regulation of Osteogenesis
Rationale -  LPA, acting through LPA receptors, has been shown to stimulate nodule 
formation and mineralization in hMSC-TERT cell cultures in vitro (Lui 2010). Studies 
from Gennero laboratory suggest that LPAi influences bone formation both qualitatively 
and quantitatively and that, in vivo, absence of LPAi results in decreased osteogenesis. 
On the other hand, Lui et al. 2010 found that absence of LPA4 increased trabecular bone 
volume, number and thickness, consistent with the ability of LPA4 to inhibit osteoblastic 
differentiation. Furthermore, LPA has been shown to elevate [Ca2+]j in several osteoblast­
like cells lines. However, the mechanisms underlying LPA-induced Ca2+ signaling in 
primary rat osteoblasts is not understood. In summary, although much is known about 
LPA effects in numerous osteoblast-like cell lines, little is known about receptor 
expression, signaling, function and osteogenesis in primary osteoblasts.
Objectives:
I. Characterize LPA receptor expression in osteoblasts.
II. Examine the signaling pathways involved in LPA-induced elevations of 
[Ca ]j in osteoblasts.
III. Investigate the role of LPA receptors in regulating osteoblast 
differentiation and bone formation (osteogenesis).
Hypotheses:
I. LPA receptors are present on cells of the osteoblast lineage.
II. Activation of LPA receptors promotes [Ca2+]j signaling and osteogenesis.
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1.6.2 Signaling Pathways Underlying LPA Receptor Activation in Osteoblasts
Rationale -  Activation of LPA receptors on osteoblasts leads to the formation of plasma 
membrane blebs (Panupinthu et al. 2007). Blebs, like lamellipodia and filopodia are 
cytoskeletal-regulated cell surface projections of the plasma membrane. Membrane 
blebbing is known as zeiosis, which comes from the Greek word Zsico meaning “to boil 
over” (Costero and Pomerat 1951), a process associated with differentiation, mitosis, 
motility, cytokinesis and apoptosis in numerous cell types (Fackler and Grosse 2008; 
Godman et al. 1975). Osteoblasts exhibit membrane blebbing during bone healing 
experiments in vivo (Olmedo et al. 1999). However the molecular mechanisms that 
govern LPA-induced actin-mediated blebbing in osteoblasts are poorly understood. 
Objective: To investigate the mechanism(s) underlying LPA-mediated osteoblasts 
membrane blebbing.
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CHAPTER TWO
ACTIVATION OF LYSOPHOSPHATIDIC ACID-l-RECEPTOR 
ON OSTEOBLASTS INDUCES RELEASE OF Ca2+ FROM 
INTRACELLULAR STORES AND ENHANCES OSTEOGENESIS1
1 Material from this chapter is in preparation for submission for publication.
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2.1 Chapter Summary
Lysophosphatidic acid (LPA) is simple bioactive lipid that mediates diverse 
physiological and pathological processes. LPA can be produced by activated platelets, 
fibroblasts, osteoblasts and cancer cells, influencing reproduction, wound healing, 
atherosclerosis and cancer metastasis to bone. The effects of LPA are mediated by at least 
six G protein-coupled receptors, LPAi-6. Although several studies have reported effects 
of LPA on osteoblast-like cell lines, little is known about LPA receptors, signaling or 
functions in primary osteoblasts. Expression of LPA receptors in primary rat calvarial 
cells and two osteoblast-like cell lines (MC3T3-E1 and UMR-106) was investigated 
using RT-PCR. Transcripts encoding LPAj were identified in calvarial osteoblasts and 
both cell lines; whereas, LPA3 was detected only in UMR-106 cells and LPA4 in primary 
osteoblasts and MC3T3-E1 cells. To determine whether or not LPA stimulates the 
mobilization of intracellular calcium ([Ca2+]j) cells were loaded with the fluorescent 
probe indo-1. In both primary osteoblasts and UMR-106 osteoblast-like cells, LPA 
induced transient elevation of [Ca ]i, lasting -100 s. Amplitude of the calcium transient 
was concentration dependent, with half-maximal effects at -20 nM LPA in both cells 
types. Elevation of [Ca ]j was inhibited by the LPA1/3 antagonists VPC32183 and 
Ki 16427. LPA still induced elevation of [Ca ]i in the absence of extracellular Ca . 
Moreover, pretreatment with the SERCA (sarco/endoplasmic reticulum calcium-ATPase) 
inhibitor thapsigargin abolished responses, indicating release of calcium from 
intracellular stores. In addition, pretreatment with pertussis toxin suppressed LPA- 
induced elevations in [Ca ]i, consistent with signaling through Gj. Alkaline phosphatase 
activity and mineralization were quantified in cultures of calvarial osteoblasts induced to
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differentiate with ascorbic acid and P-glycerophosphate. Although there was no 
significant effect of LPA when added to serum-containing culture medium, the 
competitive LPA1/3 antagonist Ki 16425 attenuated both alkaline phosphatase activity and 
mineralization. Moreover, the effect of Ki 16425 was rescued by excess exogenous LPA, 
arguing against the possibility of off-target actions. These data demonstrate for the first
0-4-time that LPA acts through Gi/0-coupled LPAi to induce the release of Ca from 
intracellular stores and activation of LPAi stimulates osteoblast differentiation and bone 
formation.
2.2 Introduction
Osteoblasts play a crucial role in bone formation in both physiological and 
pathophysiological conditions (Harada and Rodan 2003). An abundance of autocrine and 
paracrine signaling molecules are present in the bone microenvironment, where they 
regulate osteoblast proliferation, differentiation and function (Hata et al. 2011). 
Lysophosphatidic acid (LPA) is an intermediate in phospholipid metabolism, derived 
from the hydrolysis of plasma membrane phospholipids (Mills and Moolenaar 2003). 
There is growing evidence that LPA acts on osteoblasts.
LPA was first identified over 20 years ago as a smooth muscle-contracting 
molecule (Tokumura et al. 2002). It is now accepted that LPA exerts growth factor- and 
hormone-like biological effects in a number of cell types (Goetzl and An 1998; Jalink, 
Hordijk, and Moolenaar 1994). LPA is released by numerous cell types, including 
activated platelets, and is present in mammalian serum (bound to albumin) at 
concentrations of ~l-5 pM (Eichholtz et al. 1993). Plasma LPA concentrations in healthy
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individuals are considerable lower, at ~ 85 nM (Hosogaya et al. 2008), but are elevated at 
sites of injury or inflammation (Gardell, Dubin, and Chun 2006). We have recently 
shown that osteoblasts can synthesize and release LPA in response to activation of P2X7 
receptors (Panupinthu et al. 2008), which are ATP-gated cation channels. Thus, LPA may 
function as a paracrine factor to regulate osteoclast function (Lapierre et al. 2010), as an 
autocrine factor to regulate osteoblast function.
In other cell types, the effects of LPA are mediated through activation of six well 
characterized G protein-coupled receptors, termed LPAi -  LPA6, however existence of 
other LPA receptors has been suggested, including an intracellular receptor PPARy 
(Okudaira, Yukiura, and Aoki 2010). Stimulation of LPA receptors can activate a variety 
of signaling pathways by coupling, in a cell-specific manner, to several G proteins, 
including Gj/0 Gq/n, Gs and G12/13 (Mills and Moolenaar 2003). In turn, these G proteins 
act through downstream effectors and second messengers, including Rho, cyclic AMP 
and Ca . In the present study, we focused on Ca signaling by LPA in osteoblastic cells.
4̂-Ca is a critical second messenger, regulating diverse cell processes including mitosis,
• *74-gene expression and motility. As well, Ca signaling has recently been recognized to 
play an important role in osteoblast differentiation (Stem 2006).
Previous studies have demonstrated that several osteoblast-like cell lines express 
LPA receptors and respond to the addition of exogenous LPA. LPA elevates [Ca ]; in 
hMSC-TERT cells (a genetically modified cell line), effects that were attenuated by the 
LPAi/3-selective antagonist Ki 16425 (Liu et al. 2010). LPA also elicits a rise of [Ca2+]iin 
SaM-1 human osteoblastic cells (Aki et al. 2008) and the MC3T3-E1 osteoblast-like cell 
line (Waters et al. 2007). However, whether or not LPA induces calcium release in
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primary osteoblasts and the pathways underlying LPA-induced Ca2+ signaling in these 
cells is currently unknown.
Recently, studies with mice lacking specific LPA receptors have provided insights 
into the function of these receptors in bone development. LPA] deletion results in ~ 50% 
neonatal lethality, 30% reduction in overall body size, and craniofacial deformities such 
as shorter snouts and widely spaced eyes (Contos et al. 2000). A more recent 
investigation has reported additional skeletal abnormalities, including vertebral 
calcification, thoracic spine closure, stemo-distal rib fusion and malformed sternum. RT- 
PCR analysis showed decreased osteoblast differentiation markers in the radius and 
femur of these mice; however, expression of Runx2 (a transcription factor, required for 
initial osteoblast differentiation) was unchanged (Gennero et al. 2011). On the other 
hand, LPA4-deficient mice show increased trabecular bone volume, number and thickness 
(Liu et al. 2010). These findings suggest that multiple LPA receptors regulate osteoblast 
function. However, in these mouse models, receptors were absent throughout 
development and in all tissues; thus, the possibility exists that receptor deletion caused 
secondary effects that in turn affected osteoblast function.
To directly examine a role for LPA signaling in bone function, we investigated for 
the first time the mechanisms underlying LPA-induced Ca2+ signaling in primary 
osteoblasts and compared these responses to those in UMR-106 osteoblast-like cells. 
Activation of LPA receptors led to rapid elevation of [Ca2+]j. The rise in [Ca2+]j was
found to be: 1) abolished by selective LPA1/3 receptor antagonists, 2) due to release from 
intracellular stores, and 3) mediated by pertussis toxin sensitive G-protein. Moreover, an 
LPA 1/3 antagonist suppressed alkaline phosphatase activity and mineralization in
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differentiating cultures of calvarial osteoblasts (which do not express LPA3). These 
findings support a direct role for LPAi on osteoblasts in mediating the stimulatory effects 
of LPA on osteogenesis.
2.3 Materials and Methods
2.3.1 Materials
a-Minimum essential medium (a-MEM), heat-inactivated fetal bovine serum 
(FBS), antibiotic solution (10,000 units/ml penicillin, 10,000 pg/ml streptomycin sulfate, 
and 25 pg/ml amphotericin B, TRIzol reagent, indo-l-AM, UTP (uridine 5'-triphosphate) 
and DPBS (Dulbecco’s Phosphate-Buffered Saline IX) were obtained from Invitrogen. 
Collagenase type II, BAPTA-AM (l,2-bis(2-amino-5-fluorophenoxy)ethane-Ar,A,iV'vV'- 
tetraacetic acid tetrakis(acetoxymethyl) ester), EGTA (ethylene glycol-bis(P-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid tetrasodium salt), naphthol AS-MX phosphate, Fast Red 
B salt, pertussis toxin (reconstituted in 0.5 M NaCl in 0.1 M sodium phosphate buffer at 
pH 7.0), and LPA (l-oleoyl-jyi-glycero-3-phosphate) were purchased from Sigma- 
Aldrich. Bovine albumin (crystallized) was from MP Biomedicals. RNA was purified 
from cells using RNeasy Mini Kit from Qiagen. The LPA1/3 antagonists, VPC32183 and 
Ki 16425, were from Avanti Polar Lipids, Inc. and Cayman Chemical, respectively. Stock 
solutions of Na+-HEPES buffer were prepared with 135 mM NaCl, 5 mM KC1, 1 mM 
MgCh, 1 mM CaCh, 10 mM glucose, and 20 mM HEPES, 290 ± 5 milliosmoles/liter, pH 
7.30 ± 0.02. Stock solutions of Ki 16425 were prepared in dimethyl sulfoxide (DMSO). 
Stock solutions of LPA and VPC32183 were prepared in phosphate-buffered saline 
(PBS) containing bovine albumin (3% w/v) and aliquots were stored at -80°C.
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2.3.2 Cells and cell culture
Calvarial cells were isolated from neonatal Wistar rats (Charles River, St. 
Constant, QC, Canada) using sequential collagenase digestion as described (Bellows and 
Aubin 1989), with modifications. Because large yields of cells are obtained from rats and 
the system has been extensively characterized, rat cultures were utilized. Briefly, rat 
calvariae were dissected aseptically, stripped of periosteum and loosely adherent soft 
connective tissue, washed three times in cold phosphate-buffered saline (PBS) and 
minced. The minced fragments from ~12 calvariae were digested at 37°C in 6 ml of 
collagenase mixture in an incubator shaker at 100 rpm. After 10 min, the collagenase 
mixture was removed, discarded and replaced with fresh collagenase mixture. After 
additional 10 min shaker incubation, the collagenase mixture was collected, fresh 
collagenase mixture was added to the calvarial fragments and the process repeated for 10, 
10, 20 and 20 min intervals. Upon completion of shaker intervals, the calvarial fragments 
were discarded and the collected collagenase mixtures were sedimented at 1000 x g for 5 
min. Supernatant was removed and the pellet of cells was then resuspended in 5 ml of 
serum-supplemented medium. Freshly isolated calvarial cells were plated in T-25 flasks 
at a density of 1.5 x 104 cells/cm2 and maintained in aMEM with 10% FBS and 1% 
antibiotic solution (culture medium). After 3 d, undifferentiated cultures were trypsinized 
and plated as required.
For fluorescence measurement of [Ca ];, undifferentiated calvarial cells were
transferred to 60 x 15 mm Falcon dishes at a density of 1.5 x 104 cells/cm2 in culture 
medium. After 3 d, cells were utilized for spectrofluorimetry as described below. For RT- 
PCR analyses, undifferentiated calvarial cells were seeded on six-well plates at a density
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of 3 x 104 cells/cm2 supplemented with culture medium. After an additional 3 d, 
undifferentiated calvarial cell cultures were lysed using TRIzol reagent and lysates were 
stored at -  80 °C.
For studies of in vitro osteogenesis, calvarial cultures were induced to 
differentiate as follows. Undifferentiated primary cultures were seeded on Nunclon™A 
Surface (Thermo Fisher Scientific) six-well plates at a density of 3 x 104 cells/cm2. After 
an additional 3 d, culture medium was supplemented with ascorbic acid (50 pg/ml) and P- 
glycerophosphate (2 mM) (defined as day 0). Cells were then cultured for up to 4 weeks 
(together with test substances or vehicles in supplemented medium, which was changed 
every 2 -  3 d.
The UMR-106 rat and MC3T3-E1 (Subclone 4) murine osteoblast-like cell lines 
were obtained from American Type Culture Collection (Rockville, MD, USA). Cells 
were cultured in a-MEM supplemented with heat-inactivated FBS (10% vol/vol) and 
antibiotic solution (1% vol/vol) and incubated in a humidified 95% air/5% CO2 
environment at 37°C. UMR-106 cells were subcultured twice weekly and 48 h prior to 
experiments, cells were plated and grown to 70-100% confluence in 60 x 15 mm Falcon 
dishes. MC3T3-E1 cells were subcultured twice weekly and 48 h prior to experiments, 
cells were plated on 35 mm No. 0 MatTek glass bottom culture dishes at a density of 3 x 
104 cells/cm2.
2.3.3 RT-PCR Analysis of LPA Receptor Expression
To obtain RNA from ovary and small intestine, female neonatal Wistar rats were 
sacrificed by decapitation, and tissues were harvested immediately, rinsed with warm
saline solution and stored at -80 °C until RNA extraction. Total RNA was extracted from
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intestine, ovary, rat calvarial osteoblasts, MC3T3-E1 cells and UMR-106 cells using 
TRIzol reagent (Invitrogen) and RNeasy mini kits (Qiagen, Chatworth, CA), according to 
manufacturer’s directions. Samples were treated with DNase I, Amplification Grade 
(Invitrogen) for 15 min at room temperature.
First-strand complementary DNA (cDNA) was synthesized from 10 pg of total 
RNA using olig(dT)2o primer and Superscript III Reverse Transcriptase (Invitrogen) for 
50 min at 50°C and 15 min at 70°C. Control reactions were processed in the absence of 
reverse transcriptase (RT-) or without template (No Template). PCR was performed in a 
final volume of 20 pi containing the cDNA, following manufacturer’s directions, under 
the following conditions: 34 cycles at 95°C, 56.1°C (LPA2,3), 60.2°C (LPA^), 65.2°C 
(LPA5), or 63.7°C (LPAi, p-actin). Specific primers for the receptors LPAi/Edg2, 
LPA2/Edg4, LPA3/Edg7, LPA4/GPR23, LPA5/GPR92 and LPA6/p2y5, and J3-Actin are 
listed in Table 2.1. Amplification products were electrophoresed on 2% agarose gels 
(Invitrogen) containing 0.1% ethidium bromide and visualized using ImageMaster VDS 
(Pharmacia Biotech, Piscataway, NJ).
2.3.4 Fluorescence measurement of [Ca2+]j
Changes in [Ca ]i were measured using spectrofluorimetry, as previously 
described (Santhanagopal et al. 2001). Briefly, undifferentiated calvarial cells or UMR- 
106 cells were loaded with indo-1 by incubation with 2 pg/ml indo-l-AM for ~30 min at 
37°C. Subsequently, cells were washed with Na+ solution and harvested by exposure to a 
nominally Ca2+-free buffer containing trypsin (0.05%) and EDTA (0.05 mM). After ~3 
min, conditioned medium was added to halt trypsin activity. Cells were
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Table 2.1 Primers for RT-PCR















AGAGTT GC AAGGC AC AAGGT
353 NM_001106940.1 1
LPA5/GPR92 TCCTACTGGCCAACCTCATC 
G AAGT AGCCTCT GGCT GGT G
348 XM 001063300.1 1




GGGGCC AC ACGC AGCT C ATT
338 NM_031144.2 3
1 Kim, M. K., H. Y. Lee, K. S. Park, E. H. Shin, S. H. Jo, J. Yun, S. W. Lee, Y. H. Yoo, 
Y. S. Lee, S. H. Baek, and Y. S. Bae. 2005. Lysophosphatidic acid stimulates cell 
proliferation in rat chondrocytes. Biochem Pharmacol 70: 1764-71.
2 Designed by Dr. A. Pereverzev, The University of Western Ontario.
3 Moller, T., J. J. Contos, D. B. Musante, J. Chun, and B. R. Ransom. 2001. Expression 
and function of lysophosphatidic acid receptors in cultured rodent microglial cells. J  
Biol Chem 276: 25946-52.
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then resuspended in HEPES-buffered minimum essential medium. For [Ca2+]j 
measurement, aliquots of 1 ml of cell suspension were sedimented and resuspended in 2 
ml of Na+ solution in a continuously stirred fluorometric cuvette maintained at 37°C. Test 
substances were added directly to the cuvette.
[Ca ]j was monitored using a dual-wavelength spectrofluorimeter (Model RF- 
M2004, from Photon Technology International, South Brunswick, NJ) at 355 nm 
excitation and emission wavelengths of 405 and 485 nm. The system software was used 
to calculate the ratio, R, which is the fluorescence intensity at 405 nm divided by the 
intensity at 485 nm. [Ca2+]j was determined from the relationship [Ca2+] = Kd[(R- 
Rmin)/(Rmax-R)]P, where Ka (for the indo-l-Ca2+ complex) was taken as 250 nm, Rmjn and 
Rmax were the values of R at low and saturating concentrations of Ca2+, respectively, and 
P was the ratio fluorescence at 485 nm measured at low and saturating Ca2+ 
concentrations. Amplitude of Ca transients was quantified as the maximal elevation of 
[Ca ]i above resting levels.
2.3.5 Cytochemical Analyses of Alkaline Phosphatase (ALP) Activity and Mineral 
Deposition
To quantify in vitro osteogenesis, differentiating calvarial cell cultures were fixed 
at various times with 4% neutral buffered formalin overnight at 4°C. ALP activity was 
revealed using a mixture of 0.25 mM naphthol AS-MX phosphate and 1.25 mM Fast Red 
B salt in 0.1 M Tris-HCl, pH 8, for 1 h in the dark. To demonstrate mineral deposition, 
the same cultures were stained with 2.5% wt/vol silver nitrate solution (von Kossa 
staining) for 1 h with exposure to light. Images of rat calvarial cell cultures were captured 
using a microscope (SMZ1500; Nikon) with Plan APO objective (0.1 NA) attached to a
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charge-coupled device camera (CoolSNAP; Roper Scientific). Mineralized and ALP- 
positive areas were quantified from nine fields per well. Sizes of acquisition fields and 
color balance were standardized and 2D images were analyzed using Image Master 
software (Photon Technology International).
2.3.6 Data Analysis and Statistics
All data were from 3-5 independent experiments each performed in triplicate or 
quadruplicate. Results are presented as representative traces or gels, or as means ± 
standard error of the mean (SEM). Sigmoid curves were fit by nonlinear regression using 
Prism (GraphPad Software, Inc., San Diego, CA). Comparisons among means were 
performed by one-way analysis of variance (ANOVA) followed by a Tukey-Kramer 
multiple comparisons test, or two-way ANOVA followed by a Bonferroni multiple 
comparisons test. Differences were accepted as statistically significant at p <  0.05.
2.4 Results
2.4.1 Expression of LPA receptors in primary osteoblasts and osteoblastic cells
Expression of LPA receptors in osteoblasts was investigated by RT-PCR. 
Transcripts encoding LPAi were identified in all cell types (primary rat calvarial 
osteoblasts (RCO), MC3T3-E1 and UMR-106 cells), whereas LPA3 was detected only in 
UMR-106 cells (Fig. 2.1). LPA4 was found only in primary rat calvarial osteoblasts and 
MC3T3-E1 cells. LPA6 was detected in primary rat calvarial osteoblasts and UMR-106 
cells. Transcripts encoding LPA2 were not observed in any of the bone cell systems, but 
were detectable in ovary. Transcripts encoding LPA5 were also not observed; however, 
only a weak signal was observed in small intestine (positive control tissue).
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Figure 2.1 Expression of LPA receptors in osteoblastic cells. RNA was isolated from 
rat intestine, ovaries, primary cultures of rat calvarial osteoblasts (RCO, undifferentiated). 
MC3T3-E1 murine osteoblast-like cells, and UMR-106 rat osteoblast-like cells. The 
samples were divided into those that did (+) or did not (-) undergo reverse transcription 
(RT). RT-PCR was then carried out to detect mRNA transcripts for LPA receptors or |3- 
actin. Transcripts encoding LPA] were identified in all osteoblastic cells, whereas LPA3 
was detected only in IJMR-106 cells. LPA4 was detected only in primary osteoblasts and 
MC3T3-E1 cells. LPA(, was detected in primary osteoblasts and UMR-106 cells. There 
was no amplification product in samples that did not undergo reverse transcription or did 
not contain template. Data are representative of the results obtained from three 
independent experiments.
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2.4.2 LPA elevates [Ca ], in osteoblasts in a concentration-dependent manner
A i
We investigated the effects of LPA on [Ca ]\ in primary rat calvarial osteoblasts 
and UMR-106 cells using spectrofluorometry. Cells were loaded with calcium-sensitive 
fluorescent probe indo-1. In both cell types, LPA (10 nM -  10 pM) caused a rapid 
elevation of [Ca ]j from resting levels of -100 nM to maximum amplitudes of 200-400 
nM (Fig. 2.2 Ai and Bi). This was followed by a more gradual return of [Ca ]j to resting 
levels. The amplitude of responses was quantified as the peak elevation of [Ca2+], above
resting levels. Data were concentration-dependent with EC50 of 25 nM and 14 nM LPA 
for primary osteoblasts and UMR-106 cells, respectively (Fig. 2.2 Aii and Bii).
2.4.3 LPAi/3-selective antagonists VPC32183 and Kil6425 attenuate LPA-induced 
Ca2+ signaling
We next considered the possible role of LPA1/3 receptors in the LPA-induced 
elevation of [Ca2+]j. VPC32183 or Ki 16425 are highly selective dual LPA1/3 antagonists. 
VPC32183 is an LPA analog (Heasley et al. 2004); whereas Ki 16425 was isolated from a 
low-molecular weight compound library and is chemically dissimilar to LPA (Ohta et al. 
2003). Where indicated, rat calvarial osteoblasts or UMR-106 cells were pretreated with 
VPC32183 (1 pM), Ki 16425 (10 pM) or vehicle for 250 s. Cells were then challenged 
with LPA (100 nM) (Fig 2.3 Ai, Bi and Ci). In some experiments, responses to UTP (10 
pM) were evaluated to assess specificity of the antagonists. UTP activates certain P2Y 
receptors, such as P2Y2, which is a Ca mobilizing G protein-coupled receptor found in 
primary osteoblasts (Orriss, Bumstock, and Arnett 2010) and UMR-106 cells (Gallinaro, 
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Figure 2.2 LPA elevates [Ca2 ]j in osteoblasts in a concentration-dependent manner.
Primary cultures of rat calvarial osteoblasts (Primary) or UMR-106 osteoblast-like cells 
(UMR) were loaded with Ca2+-sensitive dye indo-1 and suspended in Na+ solution in a 
fluorometric cuvette at 37°C with continuous stirring. Ai and Bi Where indicated by the 
arrows, vehicle (Control) or LPA (100 nM) was added directly to the cuvette. Aii and Bii 
Responses to the indicated concentrations of LPA were quantified as the peak elevation 
of [Ca2+]i above resting levels (A Ca2+). Data are means ± SEM, n = 3 - 5 independent 
preparations. Sigmoid curves were fit by nonlinear regression. The EC50 for primary 
osteoblasts was 25 nM and for the UMR-106 cells was 14 nM LPA.
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Figure 2.3 LPA 1/3-selective antagonist VPC32183 attenuates LPA-induced Ca2+ 
signaling in osteoblastic cells. Primary cultures of rat calvarial osteoblasts (Primary) or 
UMR-106 osteoblast-like cells (UMR) were loaded with Ca2+-sensitive dye indo-1 and 
suspended in Na+ solution in a fluorometric cuvette. Ai, Bi and Ci Samples were 
pretreated with vehicle (Veh) or VPC32183 (VPC, 1 pM) for 250 s, before being 
challenged with LPA (100 nM) or UTP (10 pM) at the time indicated by the arrows. Aii, 
Bii and Cii Responses were quantified as the peak elevation of [Ca2+]i above resting 
levels (A Ca2+). Data are means ± SEM, n = 3 - 4 independent preparations. * indicates p  
< 0.05 for the effect of VPC32183. VPC32183 significantly attenuated responses to LPA. 
Surprisingly, VPC32183 also supressed responses to the P2Y agonist UTP.
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Although VPC32183 virtually abolished LPA-induced [Ca2+]j elevation in UMR- 
106 cells, it only partially blocked the Ca response in primary osteoblasts (Fig. 2.3 Ai 
and Aii). In addition, VPC32183 significantly attenuated the response to UTP in UMR- 
106 cells, indicating previously unreported lack of specificity for LPA1/3 (Fig. 2.3 Ci and 
Cii). In contrast to VPC32183, Ki 16425 almost completely inhibited LPA-induced 
elevation of [Ca2+]j in primary osteoblasts (Fig. 2.4). Moreover, Ki 16425 had no 
significant effect on the amplitude of the response to UTP, indicating specificity. For 
these reasons, Ki 16425 was used for the functional studies described in section 2.4.6 
below.
Taken together, these data establish that LPA-induced [Ca ]j elevation in UMR- 
106 cells is due to activation of LPAi and/or LPA3. On the other hand, in primary
A I
osteoblasts, which lack LPA3, Ca responses likely arise exclusively by activation of 
LPAi.
2.4.4 Source of Ca2+ underlying LPA-induced elevation of [Ca2+]j
9+ 9+Agonist-induced [Ca ]; elevation can arise by influx of Ca across the plasma
9+membrane or release of Ca from intracellular stores. The mechanism underlying LPA- 
induced [Ca ]j elevation in osteoblastic cells is controversial, with both influx (Grey et 
al. 2001) and release (Aki et al. 2008) being proposed.
To determine the source of Ca giving rise to LPA-induced [Ca ]i elevation in 
our systems, we first investigated the effect of chelation of extracellular Ca with EGTA. 
Primary osteoblasts and UMR-106 cells were bathed in nominally Ca2+-free Na+ solution 
for EGTA treatments and Na+ solution for vehicle treatments. Samples were treated 











Figure 2.4 LPAi/3-selective antagonist Kil6425 attenuates LPA-induced Ca2+ 
signaling in primary osteoblasts. Primary cultures of rat calvarial osteoblasts (Primary) 
were loaded with Ca2+-sensitive dye indo-1 and suspended in Na+ solution in a 
fluorometric cuvette. Ai and Bi Samples were pretreated with vehicle (Veh) or Ki 16425 
(Ki, 10 pM) for 250 s, before being challenged with LPA (100 nM) or UTP (10 pM) at 
the time indicated by the arrows. Aii and Bii Responses were quantified as the peak 
elevation of [Ca2+]j above resting levels (A Ca2+). Data are means ± SEM, n = 3 
independent preparations. * indicates p  < 0.05 for the effect of Ki 16425. Ki 16425 
abolished responses to LPA. In contrast to VPC32183, Ki 16425 had no significant effect 
on responses to the P2Y agonist UTP.
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Figure 2.5 Extracellular EGTA does not affect LPA-induced Ca2+ signaling. Primary 
cultures of rat calvarial osteoblasts (Primary) or UMR-106 osteoblast-like cells (UMR) 
were loaded with Ca2+-sensitive dye indo-1 and suspended in Na+ solution with or 
without Ca2+. Ai and Bi Samples in Ca2+-containing Na+ solution were treated with 
vehicle (Veh) and LPA (100 nM) at the times indicated by the arrows. Samples in 
nominally Ca2+-ffee Na+ solution were treated with EGTA (0.5 mM) and LPA (100 nM) 
at the times indicated by the arrows Aii and Bii Responses to LPA were quantified as the 
peak elevation of [Ca2+]i above resting levels (A Ca2+). Data are means ± SEM, n = 3 - 4  
independent preparations. EGTA had no significant effect on the amplitude of the LPA- 
induced Ca2+ transient.
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LPA (100 nM) (Fig. 2.5). EGTA did not significantly affect the amplitude of the response 
to LPA in either cell type, arguing against the possibility of influx through plasma 
membrane channels.
We next examined the effect of chelation of cytosolic Ca with BAPTA. Cells 
were incubated with BAPTA-AM (50 pM) or its vehicle (DMSO), along with Ca2+- 
sensitive dye indo-1, in serum-free medium for 30 min prior to challenging the cells with 
LPA. Samples were subsequently challenged with LPA (100 nM). In contrast to the lack 
of effect of extracellular EGTA, cytosolic BAPTA abolished the LPA-induced elevation 
of [Ca ]i in both primary osteoblasts and UMR-106 osteoblast-like cells (Fig. 2.6). These 
data are consistent with release of Ca from intracellular stores and help rule out the 
possibility that LPA induces sustained influx of Ca from the extracellular medium.
Finally, we investigated the effect of depleting intracellular Ca stores using 
thapsigargin, a potent and selective inhibitor of the sarco-endoplasmic reticulum Ca - 
ATPase (SERCA) (Treiman, Caspersen, and Christensen 1998). Rat calvarial osteoblasts 
and UMR-106 cells were treated with thapsigargin (1 pM) or its vehicle (DMSO). 
Thapsigargin induced a large transient elevation of [Ca2+]j, due to block of Ca2+ reuptake 
into intracellular stores (Fig. 2.7). [Ca ]j then returned slowly towards resting levels, due 
presumably to activity of the plasma membrane Ca -ATPase. Following depletion of 
Ca2+ stores, LPA (100 nM) failed to induce elevation of [Ca2+]j.
Taken together, these findings establish that most if not all of LPA-induced 























Figure 2.6 Cytosolic BAPTA abolishes LPA-induced elevation of [Ca2+] ¡. Primary 
cultures of rat calvarial osteoblasts (Primary) or UMR-106 osteoblast-like cells (UMR) 
were loaded with Ca2+-sensitive dye indo-1 along with BAPTA-AM (50 pM) or its 
vehicle (Veh). Cells were then harvested and suspended in Na+ solution in a fluorometric 
cuvette. Ai and Bi Samples were challenged with LPA (100 nM) at the time indicated by 
the arrows. Aii and Bii Responses to LPA were quantified as the peak elevation of [Ca2+]j 
above resting levels (A Ca2+). Data are means ± SEM, n -  3 - 4  independent preparations. 
* indicates p  < 0.05 for the effect of BAPTA. The cytosolic Ca2+ chelator BAPTA 


















“7.+Figure 2.7 Thapsigargin abolishes LPA-induced elevation of [Ca ]i. Primary cultures 
of rat calvarial osteoblasts (Primary) or UMR-106 osteoblast-like cells (UMR) were 
loaded with Ca2+-sensitive dye indo-1 and suspended in Na+ solution in a fluorometric 
cuvette. Ai, Aii, Bi and Bii Samples were treated with vehicle (Veh) or the SERCA 
inhibitor thapsigargin (Thap, 1 pM) at the time indicated by the arrows. Thapsigargin 
induced a large transient elevation of [Ca2+]i, due to block of Ca2+ reuptake into 
intracellular stores. Cells were subsequently challenged with LPA (100 nM) where 
indicated by the arrows. Aiii and Biii Responses were quantified as the peak elevation of 
[Ca2+]j above resting levels (A Ca2+). Data are means ± SEM, n = 3 - 4  independent 
preparations. * indicates p  < 0.05 for the effect of thapsigargin. Depletion of intracellular 
Ca2+ stores with thapsigargin abolished responses to LPA.
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2.4.5 LPA-induced elevation of [Ca2+]j is suppressed by pertussis toxin
To determine which G protein-dependent signaling pathway mediated the 
elevation of [Ca ]i in response to activation of LPAi, we investigated the effect of
pertussis toxin (PTX). PTX acts selectively on members of the Gj and G0 families to 
ADP-ribosylate the a subunit, blocking signal transduction by uncoupling the receptor 
and G protein (Milligan 1988). Rat calvarial osteoblasts and UMR-106 cells were 
preincubated with PTX holotoxin (200 ng/ml) or vehicle overnight. Samples were 
subsequently challenged with LPA (100 nM). Selected samples were also challenged 
with the P2Y agonist UTP (10 pM) as a negative control. Many P2Y receptors couple, at 
least in part, through PTX-insensitive G proteins to inositol 1,4,5-trisphosphate (IP3) 
production and release of Ca from intracellular stores (Bumstock 2007).
In both cell types, LPA-induced [Ca ]j elevation was significantly blocked by 
pretreatment with PTX (Fig. 2.8 Ai, ii and Bi, ii). In contrast, responses to UTP in UMR- 
106 cells were not significantly affected (Fig. 2.8 Ci and Cii), consistent with signaling 
by UTP in osteoblasts at least in part through a PTX-insensitive G protein, likely Gq. 
Taken together, these findings indicate that LPA signals through Gj-coupled, calcium- 
mobilizing receptors in osteoblasts.
2.4.6 LPAx/3 antagonist Kil6425 suppresses osteogenesis in primary cultures of rat 
calvarial cells
Having established that osteoblasts in calvarial cell cultures express functional 
LPA receptors, we next investigated the effects of receptor activation on osteogenesis in 
vitro. Rat calvarial cell cultures were grown in serum-containing medium for up to 28 


























Figure 2.8 Pertussis toxin suppresses LPA-induced elevation of [Ca ]j. Primary 
cultures of rat calvarial osteoblasts (Primary) or UMR-106 osteoblast-like cells (UMR) 
were incubated overnight with pertussis toxin (PTX, 200 ng/ml) or its vehicle (Veh). 
Cells were then loaded with Ca2+-sensitive dye indo-1 and suspended in Na+ solution in a 
fluorometric cuvette. Ai, Bi and Ci Samples were treated with LPA (100 nM) or UTP (10 
pM) at the times indicated by the arrows. Aii, Bii and Cii Responses were quantified as 
the peak elevation of [Ca2+], above resting levels (A Ca2+). Data are means ± SEM, n = 3 
- 4 independent preparations. * indicates p  < 0.05 for the effect of pertussis toxin. 
Responses to LPA were suppressed by pertussis toxin. In contrast, responses to UTP 
were not significantly affected.
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prolonged periods in the absence of serum). To induce osteogenic differentiation, the 
medium was supplemented with ascorbic acid (50 pg/ml) and P-glycerophosphate (2 
mM, a concentration sufficiently low to avoid nonspecific mineralization (Chung et al. 
1992).
To quantify bone formation, ALP-positive and mineralized areas were assessed at 
7-day intervals as described in Materials and Methods. As expected, both parameters 
increased over 28 days of culture. Cultures treated with additional LPA (1 or 10 pM) 
showed no significant difference in ALP activity or mineralization, compared to cultures 
grown in the presence of serum alone. Interestingly, Kil6425 (10 pM) supressed ALP 
activity and mineralization in cultures with serum or serum plus 1 pM LPA (Fig. 2.9). 
Importantly, a high concentration of LPA (10 pM) reversed the effects of Ki 16425, a 
competitive LPA1/3 antagonist. This observation argues against the possibility that the 
effects of Ki 16425 were due to nonspecific toxicity or off-target actions. The effects of 
Ki 16425 are clearly seen when the changes in ALP activity are plotted as a function of 
time (Fig. 2.10 A). In the presence of LPA (1 pM added to the serum-containing 
medium), Kil6425 significantly reduced ALP-positive area at days 14-28. In contrast, 
there were no significant inhibitory effects of Ki 16425 in the presence of 10 pM LPA 
(Fig. 2.10 B).
Since primary osteoblasts do not express LPA3, these effects of Ki 16425 suggest 
that activation of LPAi stimulates osteoblast differentiation and bone formation, 

















Figure 2.9 LPA1/3 antagonist KÌ16425 suppresses osteogenesis in primary cultures of 
rat calvarial cells. Primary cultures of rat calvarial cells were induced to differentiate by 
addition of ascorbic acid (50 pg/ml) and P-glycerophosphate (2 mM) to serum-containing 
medium beginning on day 0. Cells were treated with additional LPA ( 0 - 1 0  pM) as 
indicated, and exposed to the competitive LPA 1/3 receptor antagonist Ki 16425 (Ki, 10 
pM) or its vehicle (Veh). To assess osteogenesis, cultures were stained for alkaline 
phosphatase activity (ALP, red) and mineral deposits (black). A Representative images of 
cultures at day 14 of differentiation. ALP-positive area (B) and mineralized area (C) were 
quantified using 2D image analysis. Areas are expressed as a percentage of the total area. 
Data arc means ± SEM, n = 3 independent preparations. * indicates p < 0.05 for the effect 
of Ki 16425 compared to vehicle. Ki 16425 supressed ALP activity and mineralization in 
cultures with scrum or scrum plus 1 pM LPA. A high concentration of LPA (10 pM) 
reversed the effects of Ki 16425.
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Figure 2.10 Time course of the effect of Kil6425 on alkaline phosphatase activity in 
primary cultures of rat calvarial cells. Primary cultures of rat calvarial cells were 
induced to differentiate by addition of ascorbic acid (50 pg/ml) and P-glycerophosphate 
(2 mM) to serum-containing medium beginning on day 0. Cells were treated with 
additional LPA (1 or 10 pM) as indicated, and exposed to the LPA1/3 receptor antagonist 
Ki 16425 (10 pM) or its vehicle (Veh). Cultures were stained for alkaline phosphatase 
activity (ALP). ALP-positive area was quantified using 2D image analysis and expressed 
as a percentage of total area. Ki 16425 markedly suppressed ALP in cultures treated with 
1 pM LPA (A). In contrast, 10 pM LPA reversed the inhibitory effects of Ki 16425 (B), 
consistent with its mechanism of action as a competitive inhibitor at LPAi. Data are 




In this study, we investigated LPA signaling and function in osteoblasts. 
Transcripts encoding multiple LPA receptors were identified. LPA, acting through LPAi,
A »
induced transient elevation of [Ca ]j in primary osteoblasts and UMR-106 osteoblast- 
like cells. [Ca ]j elevation arose by release from intracellular stores and was sensitive to 
pertussis toxin. Kil6425, a highly selective LPA 1/3 antagonist, suppressed bone formation 
in primary cultures of osteoblasts. Taken together, our findings support a direct role for 
LPAi on osteoblasts in mediating the stimulatory effects of LPA on osteogenesis.
2.5.1 Expression of LPA receptors in osteoblasts and osteoblast-like cell lines
The pattern of expression of LPA receptors reported in the present study is 
generally in keeping with previous reports. LPAi has been identified by RT-PCR in both 
rat primary osteoblasts and UMR-106 cells (Grey et al. 2001). Similarly, LPA] and LPA2 
have been detected in primary human osteoblastic cells (Dziak et al. 2003). Moreover, 
quantitative RT-PCR revealed that LPAi and LPA4 are the two most abundant LPA 
receptor isoforms expressed in MC3T3-E1 cells (Masiello et al. 2006). To the best of our 
knowledge, ours is the first report that LPA4 and LPA6 are expressed in primary 
osteoblasts. Expression of LPA4 is in keeping with the bone phenotype of LPA4-deficient 
mice (Liu et al. 2010), and supports the possibility that this phenotype arises through a 
cell autonomous mechanism.
2.5.2 LPAi mediates LPA-induced elevation of [Ca ]; in osteoblasts
Several observations support the role for LPAi in mediating LPA-induced 
elevation of [Ca ]j in primary osteoblasts and UMR-106 cells. First, the EC50 for LPA 
was found to be ~20 nM, consistent with a high affinity interaction and LPA receptor-
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mediated effects in other systems (Van et al. 2004). Nevertheless, several LPA receptor
i
isoforms (including LPAi, LPA2 and LPA3) are capable of mediating Ca mobilization 
with high affinity in other cell systems (Valentine et al. 2008). Consequently, we 
examined the effects of VPC32183 and Ki 16425, which are reputed to be highly selective 
dual LPA1/3 antagonists (Heasley et al. 2004; Ohta et al. 2003). Both antagonists 
suppressed LPA-induced elevation of [Ca ]; in primary osteoblasts, which do not 
express LPA3, establishing the involvement of LPAi. Interestingly, VPC32183 partially
A 1
blocked P2Y-mediated [Ca ]j elevation in UMR-106 cells, raising doubt as to its
specificity for LPA1/3. This is in keeping with a recent authoritative review that 
recommended re-examination of the specificity of LPA receptors antagonists, particular 
those that are LPA analogs such as VPC32183 (Chun et al. 2010).
2.5.3 Pathway underlying LPAi-mediated elevation of [Ca2+]j in osteoblasts
We found that LPA-induced elevation of [Ca ]j in both primary osteoblasts and 
UMR-106 cells was unaffected by chelation of extracellular Ca with EGTA. In contrast, 
responses were abolished by the cytosolic Ca chelator BAPTA, arguing against a 
mechanism involving Ca2+ influx. Moreover, LPA-induced elevation of [Ca2+]i was 
abolished following depletion of intracellular Ca stores with thapsigargin, confirming 
that elevation of [Ca ]i arose by release from stores.
This conclusion is in keeping with the finding that the IP3 receptor blocker, 2- 
aminoethoxy-diphenylborate (2-APB), inhibits LPA-induced Ca2+ transients in the 
human osteoblastic SaM-1 cell line (Aki et al. 2008). However, studies using 2-APB 
should be interpreted cautiously as 2-APB is known to have nonspecific effects, blocking 
both Ca entry and release (Bootman et al. 2002). On the other hand, our findings are
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inconsistent with the conclusions of Grey and coworkers (Grey et al. 2001). They 
observed that LPA rapidly stimulates ERK1/2 phosphorylation in primary cultures of rat 
calvarial cells. LPA-induced phosphorylation was blocked by prolonged incubation (30 
min) with extracellular EGTA, but not by cytosolic BAPTA or thapsigargin, leading the 
authors to conclude that LPA induces Ca influx. However, it is possible that incubation 
with extracellular EGTA over such an extended period led to the gradual depletion of 
intracellular Ca stores and, therefore, loss of responsiveness to LPA.
We also observed that LPA-induced elevation of [Ca ]j was markedly attenuated
by pretreatment with pertussis toxin, indicating that most if not all of the response is 
mediated by signaling through Gj. This finding is in keeping with reports that various 
effects of LPA on osteoblastic cells are sensitive to pertussis toxin. These include 
ERK1/2 phosphorylation in primary rat calvarial cells (Grey et al. 2001), chemotaxis of 
MC3T3-E1 cells (Masiello et al. 2006), and osteocyte-like dendrite outgrowth from 
MLO-Y4 cells (Karagiosis et al. 2009). Nevertheless, the present study is -  to the best of 
our knowledge -  the first report that LPA-induced [Ca ]j elevation in osteoblastic cells is 
mediated by pertussis toxin-sensitive G proteins.
2.5.4 Activation of LPAi on osteoblasts enhances osteogenesis
We found that Ki 16425 supressed osteogenesis in primary cultures of calvarial 
osteoblasts induced to differentiate with ascorbic acid and organic phosphate. We are 
confident that the effects of Ki 16425 were due to LPAi antagonism for several reasons. 
Kil6425 completely blocked LPAi-induced Ca2+ signaling and, unlike VPC32183, had 
no off-target effect on P2Y-mediated responses. Moreover, our observation that the 
inhibitory effects of Ki 16425 were reversed in the presence of excess LPA further argues
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against possible nonspecific actions. In this regard, it has been reported that Kil6425, at 
the concentration used in the present study, partially activates PPARy (Durgam et al. 
2005). However, if the effects of Ki 16425 had been mediated through PPARy, then they 
would not have been reversed by excess LPA, which is itself an agonist for PPARy 
(McIntyre et al. 2003).
Our results extend recently reported findings on the skeletal phenotype of mice 
deficient in LPAi (Gennero et al. 2011). LPAif' mice exhibited low bone mass, and 
development defects of the ribs and sternum. As well, bone marrow mesenchymal 
progenitors from these mice displayed decreased osteoblastic differentiation in vitro. 
However, since these mice are global knockouts, it is difficult to rule out the possibility 
that LPAj deletion induced compensatory or secondary effects that in turn disturbed 
osteoblast function. Our findings with Ki 16425 argue against this possibility and support 
a direct role for LPAi on osteoblasts in stimulating osteogenesis.
Results of the present study are also consistent with previous findings from our 
laboratory on the mechanism underlying defective osteogenesis in mice lacking the 
ionotropic ATP receptor P2X7 (Panupinthu et al. 2008). We showed that activation of 
P2X7 receptors on primary osteoblasts leads to production of LPA and cyclooxygenase 
metabolites, which in turn contribute to the anabolic effects of P2X7 on skeletal tissues.
2.5.5 Potential pathophysiological significance of LPA signaling in bone
LPA is released during trauma and inflammation and, therefore, may play a role 
in stimulating osteogenesis during facture healing. As well, extracellular nucleotides can 
induce the synthesis of LPA by osteoblasts. Since nucleotides are released from cells in 
response to mechanical stimuli (Grol et al. 2009), it is possible that LPA plays a role in
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stimulating bone formation during skeletal mechanotransduction. LPA has also been 
implicated in the metastasis of breast and ovarian tumors to bone (Boucharaba et al. 
2004). Thus, LPA released from osteoblasts may be an important autocrine and paracrine 
mediator, physiologically regulating osteogenesis and osteoclast activity (Lapierre et al. 
2010), and pathologically contributing to metastatic bone disease.
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CHAPTER THREE
SIGNALING PATHWAYS UNDERLYING 
LYSOPHOSPHATIDIC ACID - INDUCED MEMBRANE
BLEBBING IN OSTEOBLASTIC CELLS
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3.1 Chapter Summary
In this brief Chapter, we present initial findings on the signaling pathways 
underlying lysophosphatidic acid (LPA)-induced membrane blebbing in MC3T3-E1 
osteoblast-like cells. RT-PCR presented in Chapter 2 revealed that MC3T3-E1 express 
both LPAi and LPA4, but not the LPA3 receptor isoform. Live-cell imaging using phase- 
contrast microscopy showed that LPA (1 pM) induced dynamic membrane blebbing in 
~50% of MC3T3-E1 cells. The LPA1/3 receptor antagonist Kil6425 had no significant 
effect on LPA-induced blebbing, indicating involvement of a receptor other than LPAi. 
On the other hand, chelation of cytosolic Ca2+ with BAPTA, blocked LPA-induced 
blebbing, indicating a requirement for elevation of cytosolic Ca2+. Similarly, inhibition of 
Rho-associated protein kinase (ROCK) with Y-27632 abolished LPA-induced blebbing. 
Surprisingly, pretreatment with pertussis toxin markedly enhanced LPA-induced 
blebbing, consistent with an inhibitory pathway involving Gj. Thus, LPA induces 
dynamic membrane blebbing in osteoblastic cells. LPA-induced blebbing is stimulated by 
an LPA receptor (other than LPAi), signaling through cytosolic Ca2+ and Rho-associated 
protein kinase. As well, LPA appears to activate an inhibitory pathway, dependent on Gj.
3.2 Introduction
Lysophosphatidic acid (LPA) is the smallest and structurally the least complex of 
all glycerophospholipids (Arita et al. 2008). LPA generates responses in a broad range of 
cell types and is involved in cardiovascular function, embryonic development, cancer 
invasion, neural system and skeletal development (Harper et al. 2010; Smyth et al. 2008). 
LPA signaling is mediated by at least six G protein-coupled receptors, LPAi - LPA6, that
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are expressed in multiple cells types including osteoblasts.
The bioactive lipid LPA has been shown to induce actin cytoskeleton-based 
morphological changes in numerous cells types. LPA quickly up regulated fibronectin 
matrix assembly binding sites correlated with changes in cell morphology and the actin 
cytoskeleton in MG63 human osteosarcoma cells (Zhang et al. 1994; Zhang et al. 1999). 
LPA-induced actin rearrangements and adhesion of Schwann cells involve Rho activation 
via a PTX-insensitive G protein (Weiner et al. 2001).
Studies have shown that the actin cytoskeleton plays an important role in 
osteoblast attachment and stabilization, mechanotransduction, as well as osteoblast 
differentiation (Anselme 2000; Chen and Bates 1993; McBeath et al. 2004). Furthermore, 
in response to various intra- and extracellular cues, there is reorganization of the actin 
cytoskeleton associated with the formation of membrane blebs in pancreatic acinar and 
cancer cells (Fackler and Grosse 2008; Torgerson and McNiven 1998).
Blebs are transient spherical protrusions of the plasma membrane. They are 
thought to arise from contraction of the actin cortex, which leads to localized ‘rupture’ of 
the cortex or detachment of the membrane from the cortex. The bleb is then ‘inflated’ by 
cytosol (Charras 2008). Restoration of the actin cortex leads to retraction of the bleb back 
into the cell. Blebbing is well known to be associated with apoptosis (programmed cell 
death); however, it is not essential for the initiation of apoptosis (Shiratsuchi, Mori, and 
Nakanishi 2002). Cytoplasmic blebs are increasingly emerging as characteristic of cell 
spreading, motility, mitosis and cell-cell recognition (Norman et al. 2010; Torgerson and 
McNiven 1998). Non-apoptotic membrane blebs have been observed during the mitosis 
of mesenchymal cells located in the tail of an intact living newt tadpole (Boss 1955).
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Membrane blebbing has also been observed during migration of tumor cells derived from 
human malignant melanomas (Cunningham et al. 1992). Furthermore, our laboratory has 
shown that LPA induces dynamic membrane blebbing in murine osteoblasts (Panupinthu 
et al. 2007). However, the mechanisms mediating LPA-induced membrane blebbing are 
poorly understood. Our purpose was to investigate the signaling pathways underlying 
LPA-induced blebbing in osteoblastic cells.
3.3 Materials and Methods
3.3.1 Materials
a-Minimum essential medium (a-MEM), heat-inactivated fetal bovine serum 
(FBS) and antibiotic solution (10,000 units/ml penicillin, 10,000 pg/ml streptomycin 
sulfate and 25 pg/ml amphotericin B) were obtained from Invitrogen. B APT A- AM (1,2- 
bis(2-amino-5-fluorophenoxy)ethane-A, N, N', A'-tetraacetic acid tetrakis(acetoxymethyl) 
ester), pertussis toxin (PTX, reconstituted in 0.5 M NaCl in 0.1 M sodium phosphate 
buffer at pH 7.0) and LPA (1-oleoyl- sn -glycero-3-phosphate) were purchased from 
Sigma-Aldrich. Bovine albumin (crystallized) was from MP Biomedicals. Ki 16425 was 
obtained from Cayman Chemical. Y-27632 was from EMD Bioscience, Inc. (La Jolla, 
CA) and was dissolved in dimethyl sulfoxide.
3.3.2 Cell Line
The MC3T3-E1 (subclone 4) murine osteoblast-like cell line was obtained from 
the American Type Culture Collection (Rockville, MD). Cells were cultured in a-MEM 
supplemented with FBS (10% vol/vol) and antibiotic solution (1% vol/vol) and incubated 
in a humidified 95% air/5% CO2 environment at 37°C. Cells were subcultured twice 
weekly and 48 h prior to experiments, cells were plated and grown to -70% confluency
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on 35-mm Coming culture dishes (Coming Incorporated, Coming, NY). Cells were 
incubated in serum-free medium for the final 18 h prior to experiments.
3.3.3 Time-lapse Assessment of Changes in Cell Morphology
To perform time-lapse recordings, the serum-free medium was removed and 
replaced with nominally divalent cation-free buffer consisting of the following (in mM): 
NaCl 140, KC1 5, NaHEPES 20 and glucose 10, pH 7.35 ± 0.02, 290 ± 5 
milliosmoles/liter. Dishes were placed on a heated stage and maintained at ~35 °C. Time- 
lapse experiments were carried out using an inverted phase-contrast microscope (Nikon 
Eclipse TE300, Nikon Instruments Inc., Melville, NY) using a Nikon Plan-Fluor x20 
objective (0.45 numerical aperture). Images were captured on a moderately cooled CCD 
camera (Cool SNAP cf, Photometries, Tucson, AZ) using Image Master 5 Software 
(Photon Technology International, Birmingham, NJ).
Samples were imaged for 12 min at 12 frames/min. Test substances were added 
following a 2-min control period. Membrane blebbing was quantified as the percentage 
of cells in each field exhibiting blebbing during the 10 min period following addition of 
the test substance. Fields were 320 x 240 pm and contained 36 ± 7 cells/field (mean ± 
SD, n = 144). Three fields were analyzed for each condition from each cell preparation 
and each experiment was performed on 3 independent cell preparations.
3.3.4 Statistical Analysis
Unless otherwise indicated, data are presented as means ± SEM of n independent 
experiments. Comparisons among means were performed using two-way ANOVA 
followed by a Bonferroni multiple comparisons test. Differences were accepted as 
statistically significant at p<  0.05.
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3.4 Results
3.4.1 LPA Induces Dynamic Membrane Blebbing in Osteoblastic Cells through a 
Receptor Other than LPAi
RT-PCR results presented in Chapter 2 revealed that MC3T3-E1 cells express two 
LPA receptors, LPAi and LPA4. Here, we monitored the effect of LPA on the 
morphology of MC3T3-E1 osteoblast-like cells. Cultures were placed in a stage heater 
(35°C) and bathed in nominally divalent cation-free buffer. Removal of extracellular Ca 
and Mg2+ increases the propensity of cells to exhibit blebbing (Panupinthu et al. 2007), 
likely by decreasing their adhesiveness to the substratum.
Prior to addition of LPA, few cells exhibited membrane blebs (Fig. 3.1 A). When 
cells were treated with LPA (1 pM), dramatic changes in morphology were observed, 
including cellular retraction, membrane ruffling and the formation of membrane blebs 
(Fig. 3.IB). Blebbing was dynamic, with multiple blebs enlarging and shrinking 
asynchronously (see supplementary video). The percentage of cells exhibiting dynamic 
blebbing was determined from time-lapse movies obtained during 10 min of treatment 
with vehicle or LPA (1 pM). LPA induced dynamic membrane blebbing in -50% of cells 
(Fig. 3.2, open bars).
To investigate the possible role of LPAi in LPA-mediated blebbing, we 
investigated the effect of the LPA1/3 receptor antagonist Kil6425 (10 pM). In Chapter 2, 
we found that this concentration of Kil6425 abolished LPA-induced [Ca2+]i elevation in 
primary osteoblasts, without affecting P2Y-mediated responses, indicating its efficacy 
and specificity. Ki 16425 did not block the ability of LPA to induce membrane blebbing 
(Fig. 3.2). Thus, a receptor other than LPAi (likely LPA4) mediates LPA-induced
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Fig. 3.1 LPA induces membrane blebbing in MC3T3-E1 osteoblast-like cells.
MC3T3-E1 cells were bathed in nominally divalent cation-free buffer and maintained at 
~35°C with a stage warmer. Morphology was monitored by phase-contrast time-lapse 
microscopy. A Representative field of cells. B Same field of cells, ~2 min following 
addition of LPA (1 pM). Numerous cells retracted and exhibited membrane blebs 
(arrows). In addition, some cells exhibited membrane ruffling in response to LPA.
See also supplementary video illustrating dynamic blebbing during the experiment 
illustrated in Fig. 3.1. Video begins at 0 min, LPA was added at 2 min and video ends at 
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Fig. 3.2 LPA-induced membrane blebbing in MC3T3-E1 cells is not blocked by the 
LPA1/3 antagonist Kil6425. MC3T3-E1 cells were incubated in nominally divalent 
cation-free buffer containing Kil6425 (10 pM) or its vehicle (Control) at ~35°C for 10 
min. Morphology was then monitored by phase-contrast time-lapse microscopy. After 2 
min, LPA (1 pM) or its vehicle (Veh) was added (in the continued presence of Kil6425 
or its vehicle). The percentage of cells exhibiting dynamic blebbing during the 
subsequent 10 min was determined from the time-lapse recordings. LPA significantly 
increased the percentage of blebbing cells. Kil6425 did not significantly affect this 
response. Data are means ± SEM, n = 3 independent preparations, each performed in 
triplicate. * indicates significant effect of LPA (p < 0.05).
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membrane blebbing in MC3T3-E1 cells.
3.4.2 LPA-Induced Membrane Blebbing is Suppressed by the Cytosolic Ca 
Chelator BAPTA
Signaling by several LPA receptors, including LPA4, involves elevation of [Ca ]i 
(Chang et al. 2007). Moreover, cytosolic Ca2+ regulates cytoskeletal remodeling and 
contraction in many cell types (Pettit and Fay 1998). Therefore, we considered whether 
elevation of [Ca ]i plays a role in LPA-induced membrane blebbing. MC3T3-E1 cells 
were loaded with BAPTA by incubation with BAPTA-AM (50 pM) or its vehicle 
(DMSO) for 30 min. In Chapter 2, we showed that loading osteoblastic cells with 
BAPTA, under the same conditions, virtually abolished LPA-induced elevation of 
[Ca2+]i.
Cultures were placed on the microscope stage and time-lapse images recorded for 
12 min. Whereas -50% of control cells exhibited blebbing in response to LPA (1 pM), 
only - 8% of BAPTA-loaded cells exhibited blebbing (Fig. 3.3). These data indicate that 
elevation of [Ca ]i is required for LPA-induced blebbing in MC3T3-E1 cells.
3.4.3 Inhibition of Rho-Associated Protein Kinase Abolishes Membrane Blebbing 
Induced by LPA
Rho-associated protein kinase has been shown to be both necessary and sufficient 
for cytoskeletal rearrangements associated with membrane blebbing in other systems 
(Coleman et al. 2001). Therefore, we investigated the possible involvement of Rho- 
associated protein kinase in LPA-induced blebbing in MC3T3-E1 cells using Y-27632, a 
specific inhibitor of the ROCK family of protein kinases (Ishizaki et al. 2000). Y-27632 










Fig. 3.3 The cytosolic Ca2+ chelator BAPTA inhibits LPA-induced membrane 
blebbing in MC3T3-E1 cells. MC3T3-E1 cells were incubated with BAPTA-AM (50 
pM) or its vehicle (Control) in serum-free medium for 30 min. Medium was then 
replaced with nominally divalent cation-free buffer and morphology was monitored by 
phase-contrast time-lapse microscopy. After 2 min, LPA (1 pM) or its vehicle (Veh) was 
added. The percentage of cells exhibiting dynamic blebbing during the subsequent 10 
min was determined from the time-lapse recordings. In control cells, LPA significantly 
increased the percentage of blebbing cells. There was no significant effect of LPA in 
BAPTA-loaded cells. Data are means ± SEM, n = 3 independent preparations, each 
performed in triplicate. * indicates significant effect of LPA, * indicates significant effect
#
0
Veh LPA Veh LPA
of BAPTA (p < 0.05).
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Fig. 3.4 The Rho-associated protein kinase inhibitor Y-27632 supresses LPA- 
induced membrane blebbing in MC3T3-E1 cells. MC3T3-E1 cells were incubated in 
nominally divalent cation-free buffer containing Y-27632 (10 pM) or its vehicle 
(Control) at ~35°C for 15 min. Morphology was then monitored by phase-contrast time- 
lapse microscopy. After 2 min, LPA (1 pM) or its vehicle (Veh) was added (in the 
continued presence of Y-27632 or its vehicle). The percentage of cells exhibiting 
dynamic blebbing during the subsequent 10 min was determined from the time-lapse 
recordings. In control cells, LPA significantly increased the percentage of blebbing cells. 
There was no significant effect of LPA in the presence of Y-27632. Data are means ± 
SEM, n = 3 independent preparations, each performed in triplicate. * indicates significant 
effect of LPA, # indicates significant effect of Y-27632 (p < 0.05).
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involvement of Rho-associated protein kinase mediated blebbing downstream of LPA 
receptors in MC3T3-E1 cells.
3.4.4 Pertussis toxin (PTX) potentiates LPA-induced membrane blebbing in 
MC3T3-E1 cells
To further elucidate the signaling pathway mediating LPA-induced blebbing, we 
investigated the effect of PTX. PTX acts selectively on members of the Gj and G0 
families to ADP-ribosylate the a subunit, blocking signal transduction by uncoupling the 
receptor and G protein (Milligan and Kostenis 2006). MC3T3-E1 cells were preincubated 
with PTX holotoxin (200 ng/ml) or its vehicle overnight. Cultures were then placed on 
the microscope stage and challenged with LPA (1 pM) or its vehicle. Pretreatment with 
PTX had no significant effect on blebbing in vehicle-treated cultures. In contrast, the 
percentage of cells blebbing in response to LPA increased from 46% in control cells to 
94% in cells pretreated with PTX (Fig. 3.5). Thus, in addition to stimulating blebbing 
through Ca and Rho-associated protein kinase, LPA appears to act through G; to inhibit 
blebbing in MC3T3-E1 cells.
3.5 Discussion
Membrane blebbing occurs during a number of cellular processes, including 
apoptosis, spreading, endocytosis, motility and mitosis (Dai and Sheetz 1999; Torgerson 
and McNiven 1998). In this study, we examined the signalling events underlying LPA- 
induced blebbing in MC3T3-E1 cells. We showed, for the first time, the involvement of 
cytosolic Ca in LPA-induced blebbing in cells of the osteoblast lineage. Moreover, we 








Fig. 3.5 Pertussis toxin potentiates LPA-induced membrane blebbing in MC3T3-E1 
cells. MC3T3-E1 cells were incubated overnight with pertussis toxin (PTX, 200 ng/ml) or 
its vehicle (Control) in serum-free medium. Medium was then replaced with nominally 
divalent cation-free buffer and morphology was monitored by phase-contrast time-lapse 
microscopy. After 2 min, LPA (1 pM) or its vehicle (Veh) was added. The percentage of 
cells exhibiting dynamic blebbing during the subsequent 10 min was determined from the 
time-lapse recordings. In both control and PTX-pretreated cells, LPA significantly 
increased the percentage of blebbing cells. Interestingly, PTX significantly increased the 
percentage of cells responding to LPA. Data are means ± SEM, n = 3 independent 
preparations, each performed in triplicate. * indicates significant effect of LPA, # 
indicates significant effect of PTX (p < 0.05).
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Extracellular signaling molecules that initiate membrane blebbing in various cell 
types continue to be identified. ATP has been shown to induce blebbing in numerous cell 
types, mediated by P2X7 receptors (Morelli et al. 2003). Cholecystokinin, a 
neurotransmitter and peptide hormone induces reversible blebbing of rat pancreatic acinar 
cells (Torgerson and McNiven 1998). Serum stimulates blebbing in NB2a rat 
neuroblastoma cells (Hagmann, Burger, and Dagan 1999). In this regard, LPA is a 
constituent of serum (1-5 pM) and neuroblastoma cells that are exposed to LPA exhibit 
transient blebbing (Hagmann, Burger, and Dagan 1999). These findings are consistent 
with our observation that LPA induces membrane blebbing in osteoblastic cells.
Cytoplasmic blebs are transient protrusions of the plasma membrane involving 
localized disruption of membrane-actin interaction, resulting in projection of the 
membrane driven by cytosolic hydrostatic pressure (Fackler and Grosse 2008). Non- 
apoptotic blebbing has been observed in numerous cell types; however, the signalling 
pathways mediating this effect are poorly understood. It has long been recognized that 
Ca2+ signaling regulates cytoskeletal remodeling and actomyosin contraction. Previous 
investigations revealed that the formation of membrane blebs in hepatocytes is triggered 
by agents that increase [Ca ]i (Nicotera et al. 1986). Furthermore, a rise in [Ca ]j has 
been proposed to cause membrane blebbing in endothelial cells (Geeraerts et al. 1991). 
We found that the cytosolic Ca chelator BAPTA attenuated LPA-induced membrane 
blebbing. In Chapter 2, we also demonstrated that BAPTA effectively buffered LPA- 
induced [Ca ]j elevation. Thus, our findings indicate that elevation of [Ca ]j is required 
for LPA to induce membrane blebbing in osteoblastic cells.
The Rho GTPase -  Rho-associated protein kinase (ROCK) pathway has been
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implicated in the regulation of many cellular functions including, adhesion, migration, 
cytokinesis and cell growth (Wettschureck and Offermanns 2002). Consistent with 
previous reports, we demonstrated that ROCK activity is required for LPA-induced 
membrane blebbing. Presumably, Rho GTPase activates its effector molecule, Rho- 
associated protein kinase. ROCK then phosphorylates myosin light chain, inducing 
actomyosin contraction and the formation of membrane blebs (Fackler and Grosse 2008). 
Rho signaling through ROCK has been shown to promote membrane blebbing associated 
with the motility of tumor cells (Sahai and Marshall 2003). It has also been reported that 
activation of ROCKII is sufficient to induce membrane blebbing in MCF-7 cells (Song, 
Hoang, and Chang 2002). Moreover, our lab has shown previously that Rho-associated 
protein kinase mediates blebbing downstream of LPA receptors in murine calvarial 
osteoblasts (Panupinthu et al. 2007).
Osteoblasts respond to extracellular LPA through multiple G protein-coupled 
receptors. LPA receptors couple to at least four types of G proteins. From Chapter 2, we 
know that LPA signals through LPAi-G; to elevate [Ca ]i in osteoblastic cells. In the 
present Chapter, we show that LPA induces blebbing in MC3T3-E1 cells though a 
receptor other than LPAi. Moreover, blebbing was mediated through a pathway 
dependent on Rho-associated protein kinase, implicating G12/13, which is known to signal 
through activation of Rho (Neves, Ram, and Iyengar 2002). In summary, LPA induces 
dynamic membrane blebbing in MC3T3-E1 cells. Our findings are consistent with 
blebbing being mediated by LPA4, signaling through Gq to elevation of [Ca ]j and G12/13 
to activation of Rho and Rho-associated protein kinase. LPA also appears to signal 
through Gi to activate a pathway that inhibits membrane blebbing.
99
3.6 References
Anselme, K. 2000. Osteoblast adhesion on biomaterials. Biomaterials 21: 667-81.
Arita, Y., T. Ito, T. Oono, K. Kawabe, T. Hisano, and R. Takayanagi. 2008. 
Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in 
Panc-1 cells by mobilizing cytosolic free calcium. World J  Gastroenterol 14: 
4473-9.
Boss, J. 1955. Mitosis in cultures of newt tissues. IV. The cell surface in late anaphase 
and the movements of ribonucleoprotein. Exp Cell Res 8: 181-7.
Chang, Y. J., Y. L. Kim, Y. K. Lee, S. J. Sacket, K. Kim, H. L. Kim, M. Han, Y. S. Bae, 
F. Okajima, and D. S. Im. 2007. Dioleoyl phosphatidic acid increases intracellular 
Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts. 
Prostaglandins Other Lipid Mediat 83: 268-76.
Charras, G. T. 2008. A short history of blebbing. JMicrosc 231: 466-78.
Chen, T. L., and R. L. Bates. 1993. Recombinant human transforming growth factor beta 
1 modulates bone remodeling in a mineralizing bone organ culture. J  Bone Miner 
Res 8: 423-34.
Coleman, M. L., E. A. Sahai, M. Yeo, M. Bosch, A. Dewar, and M. F. Olson. 2001. 
Membrane blebbing during apoptosis results from caspase-mediated activation of 
ROCK I. Nat Cell Biol 3: 339-45.
Cunningham, C. C., J. B. Gorlin, D. J. Kwiatkowski, J. H. Hartwig, P. A. Janmey, H. R. 
Byers, and T. P. Stossel. 1992. Actin-binding protein requirement for cortical 
stability and efficient locomotion. Science 255: 325-7.
Dai, J., and M. P. Sheetz. 1999. Membrane tether formation from blebbing cells. Biophys 
J l l :  3363-70.
Fackler, O. T., and R. Grosse. 2008. Cell motility through plasma membrane blebbing. J  
Cell Biol 181:879-84.
Geeraerts, M. D., M. F. Ronveaux-Dupal, J. J. Lemasters, and B. Herman. 1991. 
Cytosolic free Ca2+ and proteolysis in lethal oxidative injury in endothelial cells. 
Am J  Physiol 261: C889-96.
Hagmann, J., M. M. Burger, and D. Dagan. 1999. Regulation of plasma membrane 
blebbing by the cytoskeleton. J  Cell Biochem 73: 488-99.
Harper, K., D. Arsenault, S. Boulay-Jean, A. Lauzier, F. Lucien, and C. M. Dubois. 2010. 
Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: 
participation of the cyclic AMP/EPAC/Racl signaling pathway in invadopodia 
formation. Cancer Res 70: 4634-43.
Ishizaki, T., M. Uehata, I. Tamechika, J. Keel, K. Nonomura, M. Maekawa, and S. 
Narumiya. 2000. Pharmacological properties of Y-27632, a specific inhibitor of 
rho-associated kinases. Mol Pharmacol 57: 976-83.
100
McBeath, R., D. M. Pirone, C. M. Nelson, K. Bhadriraju, and C. S. Chen. 2004. Cell 
shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. 
Dev Cell 6: 483-95.
Milligan, G., and E. Kostenis. 2006. Heterotrimeric G-proteins: a short history. Br J  
Pharmacol 147 Suppl 1: S46-55.
Morelli, A., P. Chiozzi, A. Chiesa, D. Ferrari, J. M. Sanz, S. Falzoni, P. Pinton, R. 
Rizzuto, M. F. Olson, and F. Di Virgilio. 2003. Extracellular ATP causes ROCK 
I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol Biol Cell 14: 
2655-64.
Neves, S. R., P. T. Ram, and R. Iyengar. 2002. G protein pathways. Science 296: 1636-9.
Nicotera, P., P. Hartzell, G. Davis, and S. Orrenius. 1986. The formation of plasma 
membrane blebs in hepatocytes exposed to agents that increase cytosolic Ca2+ is 
mediated by the activation of a non-lysosomal proteolytic system. FEBS Lett 209: 
139-44.
Norman, L. L., J. Brugues, K. Sengupta, P. Sens, and H. Aranda-Espinoza. 2010. Cell 
blebbing and membrane area homeostasis in spreading and retracting cells. 
BiophysJ 99: 1726-33.
Panupinthu, N., L. Zhao, F. Possmayer, H. Z. Ke, S. M. Sims, and S. J. Dixon. 2007. 
P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway 
involving lysophosphatidic acid. JBiol Chem 282: 3403-12.
Pettit, E. J., and F. S. Fay. 1998. Cytosolic free calcium and the cytoskeleton in the 
control of leukocyte chemotaxis. Physiol Rev 78: 949-67.
Sahai, E., and C. J. Marshall. 2003. Differing modes of tumour cell invasion have distinct 
requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell 
Biol 5: 711-9.
Shiratsuchi, A., T. Mori, and Y. Nakanishi. 2002. Independence of plasma membrane 
blebbing from other biochemical and biological characteristics of apoptotic cells. 
JBiochem 132: 381-6.
Smyth, S. S., H. Y. Cheng, S. Miriyala, M. Panchatcharam, and A. J. Morris. 2008. Roles 
of lysophosphatidic acid in cardiovascular physiology and disease. Biochim 
Biophys Acta 1781: 563-70.
Song, Y., B. Q. Hoang, and D. D. Chang. 2002. ROCK-II-induced membrane blebbing 
and chromatin condensation require actin cytoskeleton. Exp Cell Res 278: 45-52.
Torgerson, R. R., and M. A. McNiven. 1998. The actin-myosin cytoskeleton mediates 
reversible agonist-induced membrane blebbing. J  Cell Sci 111 ( Pt 19): 2911-22.
Weiner, J. A., N. Fukushima, J. J. Contos, S. S. Scherer, and J. Chun. 2001. Regulation of 
Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic 
acid signaling. JNeurosci 21: 7069-78.
Wettschureck, N., and S. Offermanns. 2002. Rho/Rho-kinase mediated signaling in 
physiology and pathophysiology. JM ol Med 80: 629-38.
101
Zhang, Q., W. J. Checovich, D. M. Peters, R. M. Albrecht, and D. F. Mosher. 1994. 
Modulation of cell surface fibronectin assembly sites by lysophosphatidic acid. J  
Cell Biol 127: 1447-59.
Zhang, Q., O. Peyruchaud, K. J. French, M. K. Magnusson, and D. F. Mosher. 1999. 
Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho- 




4.1 Summary and Conclusions
LPA receptor expression in osteoblastic cells
Conventional RT-PCR revealed the presence of LPAi, LPA3, LPA4 and LPA6 in 
osteoblastic cells. Transcripts encoding LPAi were identified in all cell types (primary rat 
calvarial cells, MC3T3-E1 and UMR-106 cells); whereas, LPA3 was detected only in UMR-106 
cells, and LPA4 was detected only in primary and MC3T3-E1 cells. LPA6 was detected in 
primary and UMR-106 cells. These data confirm the expression of LPA receptors in osteoblasts.
1. Osteoblastic cells express multiple isoforms of LPA receptors.
2. Receptor expression varies depending on cell type.
Effects o f LPA on [Ca ], in osteoblastic cells
This report confirms previous findings in osteoblast-like cell lines and shows, for the first
2+  t t
time in primary osteoblasts, that LPA induces receptor-mediated Ca mobilization. LPA caused 
transient elevation of [Ca ]j in a concentration-dependent manner, with an EC50 of 
~20 nM LPA, consistent with a receptor-mediated effect. The LPA1/3 receptor antagonists 
VPC32183 and Ki 16425 inhibited the rise of [Ca2+]i elicited by LPA. However, VPC32183 also 
suppressed the P2Y receptor-mediated response to UTP, indicating a previously unreported lack 
of specificity for LPA1/3. Three lines of evidence indicated that LPA induces elevation of [Ca ]j 
through release from intracellular stores. First, the extracellular calcium chelator EGTA failed to 
inhibit LPA-induced elevation of [Ca2+]j. Second, the cytosolic calcium chelator BAPTA 
attenuated the rise of [Ca2+]j elicited by LPA. Third, pretreatment with the SERCA inhibitor 
thapsigargin blocked LPA-induced elevation of [Ca ]j. Lastly, pretreatment with pertussis toxm
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suppressed LPA-mduced elevations in [Ca ]*, consistent with signaling through Gj. Thus, LPA
i
signals in osteoblasts, at least in part, through Gj/0-coupled LPAi to induce the release of Ca 
from intracellular stores.
A  I
1. This is the first report that LPA elicits elevation in [Ca ]j in primary osteoblasts.
2. LPA induces release of Ca from intracellular stores.
3. LPA signals, at least in part, through an LPAj-Gj pathway.
The role o f LPA receptors in regulating osteoblast differentiation and bone formation in vitro 
In vitro osteogenesis by primary rat calvarial cells was diminished by the competitive, 
LPAi/3-selective antagonist Kil6425. Moreover, 10 pM of LPA reversed the effects of Kil6425, 
indicating specificity of the antagonist.
1. Ki16425 attenuated both alkaline phosphatase activity and mineralization in rat 
calvarial cell cultures.
2. The effects of Ki 16425 were rescued by excess exogenous LPA, arguing against the 
possibility of off-target actions.
3. LPA acts directly through LPAi on osteoblasts to stimulate differentiation and bone 
formation.
Signaling pathways underlying LPA-induced membrane blebbing in osteoblastic cells
In Chapter 3, we show that activation of LPA receptors induces membrane blebbing in 
osteoblastic cells. The LPA1/3 receptor antagonist Ki 16425 had no significant effect on LPA- 
induced blebbing. LPA-induced membrane blebbing is dependent on elevation of [Ca2+]i and 
activation of Rho-associated protein kinase. Pretreatment with pertussis toxin markedly
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enhances LPA-induced blebbing, consistent with an inhibitory pathway involving Gj.
1. LPA induces membrane blebbing in osteoblastic cells through a receptor other than 
LPAi.
2. LPA-induced membrane blebbing is dependent on [Ca ]j elevation and Rho- 
associated protein kinase activity.
3. As well, LPA appears to activate a Gj-dependent pathway that inhibits membrane 
blebbing.
4.2 Contributions of the Research to the Current State of Knowledge
Historical perspective and general significance
The ability of LPA to mediate diverse cellular functions has drawn considerable attention 
from the scientific community. Increasing evidence shows that LPA regulates bone 
development and maintenance. LPAf7' mice display craniofacial deformities such as shorter 
snouts and widely spaced eyes (Contos et al. 2000), as well as vertebral calcification, thoracic 
spine closure, rib and sternum abnormities (Gennero et al. 2011). Interestingly, LPA4 ' mice 
exhibit increased trabecular bone volume, number and thickness (Liu et al. 2010). Thus, LPA 
and the antagonistic effects of it receptors, LPAi and LPA4, may play a complex role in bone 
homeostasis. It should be noted that LPA f 1' mice are global knockouts; thus, it is possible that 
LPAi deletion induced compensatory or secondary effects that in turn disturbed osteoblast 
function. Our findings with Ki 16425 argue against such a possibility and support a direct role 
for LPA] on osteoblasts in stimulating osteogenesis.
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Possible anabolic target for the treatment o f osteoporosis
A long term goal of our studies is to improve our understanding of bone homeostasis to 
develop new approaches for the prevention and treatment of metabolic bone diseases such as 
osteoporosis. Most current osteoporosis therapies are aimed at inhibiting bone resorption and 
these treatments do not enhance bone formation. Therefore, identifying the factors that enhance 
osteoblast activity and defining the mechanisms by which they exert anabolic effects may 
advance drug development for the treatment of systemic skeletal diseases.
Activation of LPA receptors promotes osteogenesis (Chapter 2) and osteoblast survival 
(Grey et al. 2001). Moreover, our current findings may explain the decreased bone content 
(osteoporosis) observed in LPAf1' mice (Gennero et al. 2011). Thus, LPA receptors, such as 
LPAi, should be explored as possible targets for the development of novel anabolic therapies for 
the treatment of osteoporosis.
Metastases o f cancer to bone
Patients with advanced breast, ovarian and prostate carcinomas commonly experience 
cancer metastasis to bone, a primary cause of death (Mundy 2002). Bone-derived cytokines and 
growth factors are thought to enhance the invasion, proliferation and survival of cancer cells. 
Solid tumors, such as prostate cancer, metastasize to bone often causing osteoblastic metastases, 
involving osteoblast proliferation, differentiation and bone formation. Conversely, breast and 
lung cancers are generally osteolytic, due to the production of osteoclast-activating factors.
Aberrant LPA synthesis and receptor expression has been implicated in cancer 
progression and bone metastases (Mills and Moolenaar 2003). In this regard, autotaxin 
(originally identified as a tumor cell autocrine motility factor) is a major phospholipase required 
for LPA synthesis in blood (van Meeteren and Moolenaar 2007). LPA is a potent inducer of IL-
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6 and IL-8 generation in osteoblasts and cancer cells (Aki et al. 2008). These cytokines are 
known to attract, differentiate and activate osteoclasts creating osteolytic metastatic sites 
(Kinder et al. 2008). We have recently demonstrated that osteoblasts produce LPA through 
activation of P2X7 receptors (Panupinthu et al. 2008). Furthermore, our laboratory has recently 
shown that LPA enhances osteoclast survival (Lapierre et al. 2010). Thus, LPA and its receptors 
and synthetic enzymes may be targets for the prevention and treatment of tumor metastases to 
bone. Indeed, the selective LPA1/3 antagonist Ki 16425 has recently been licensed by 
Debiopharm Group (Switzerland) under the name “Debio 0719” and is in preclinical 
development as an antitumor drug (Noguchi et al. 2009; Ohta et al. 2003).
Lineage allocation o f mesenchymal stem cells between adipocytes and osteoblasts
Osteoblasts and adipocytes arise from common mesenchymal progenitor cells (Rosen and 
Bouxsein 2006). With age, the balance between adipocytes and osteoblasts in the bone marrow 
fluctuates to favour the presence of adipocytes, indicating a negative correlation between 
adipocyte and osteoblast differentiation. Depending on levels of osterix and PPARy, 
mesenchymal cells differentiate into cells of the osteoblast or adipocyte lineage (Ali et al. 2005). 
Indeed, LPA inhibits PPARy expression, reduces the expression of adipocyte markers and 
attenuates adipogenesis in the mouse preadipose cell line 3T3F442A (Simon et al. 2005). 
Moreover, expression of osterix is decreased in LPAf1' mice (Gennero et al. 2011). Taken 
together, it appears that LPA may direct mesenchymal stem cells to differentiate towards cells 
of the osteoblast lineage, consistent with our observation that Ki 16425 suppresses osteoblast 
differentiation in vitro.
Implications for fracture healing
Fracture healing is a complex processes involving the coordinated actions of numerous
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cells types (Einhom 1998). During normal wound healing, platelets become activated and 
degranulated, releasing growth factors that initiate and modulate cellular processes involved in 
wound healing (Eppley, Woodell, and Higgins 2004). During the initial stages of fracture 
healing, LPA is released from activated platelets and osteoblast precursors are exposed to 
increased levels of LPA. LPA may play a role in promoting bone growth and accelerating 
fracture healing. In addition, primary osteoblasts exposed to LPA upregulate gene products 
encoding the anti-inflammatory proteins, sST2, ST2L and heat shock protein 25 (Waters et al. 
2007). These proteins may help to control inflammation during fracture healing. In conclusion, 
it is possible that LPA receptor agonists could be used therapeutically to enhance the healing of 
skeletal injuries and in skeletal tissue engineering applications.
4.3 Limitations of the Research and Suggestions for Future Studies
In vitro investigations
In vitro studies provide important insights into fundamental mechanisms of biological 
processes. However, the technical limitations of these studies results from artifacts that may 
arise. Notably, attachment to an artificial substrate may alter cellular behaviour. In vitro 
research requires models that better simulate in vivo conditions, for example, substrates that 
better mimic the natural environment, presence of an extracellular matrix and 3D culture 
systems. In the present studies, pharmacological inhibitors were utilized to determine signaling 
pathways; these may induce nonspecific effects. It would be ideal to substantiate findings in 
Chapters 2 and 3 using LPA receptor knockout mice to elucidate which receptors mediate the 
effects of LPA on osteoblasts. A portion of our investigations were completed using osteoblast­
like and osteosarcoma cell lines. Atypical LPA receptor expression was noted in these cell lines.
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It would be desirable to validate the findings in Chapter 3 using primary osteoblasts.
LPA-induced membrane blebbing
In our investigations, we bathed cells in nominally divalent cation-free buffer to 
maximize blebbing during short term experiments (~10 min). Furthermore, we incubated the 
cells overnight in a serum-free media. To more closely resemble physiological conditions, LPA 
could be applied in the presence of divalent cations, while imaging fluorescently labeled cells 
with confocal microscopy.
Assessment o f LPA receptor signaling
•y.
Our studies focused on Ca signaling and did not fully investigate the diverse pathways 
activated by LPA receptor stimulation in osteoblasts. Further studies are required to elucidate 
the signaling pathways underlying LPA-enhanced osteogenesis and membrane blebbing. LPA 
induces ERK activation and chemotaxis in MC3T3-E1 cells in a PTX-sensitive manner 
(Masiello et al. 2006). Furthermore, LPA-enhanced proliferation in human primary osteoblasts 
involves Gi and PKC, but not ERK1/2 (Grey et al. 2001). In our investigations, activation of
I
LPA receptors induced membrane blebbing through elevation of Ca and activation of Rho- 
associated protein kinase. It is plausible that additional signaling molecules regulate different 
components of membrane blebbing. To determine whether LPA has an effect on Rac, 
osteoblasts could be treated with C3-07, a specific inhibitor of Rac. Furthermore, studies of the 
effects of LPA on the activation and subcellular localization of transcription factors may provide 
further insights as to the signaling pathways activated by LPA in osteoblasts.
Role o f LPA in osteoblastogenesis
In Chapter 2, we found that an LPA1/3 receptor antagonist suppressed mineralization and 
alkaline phosphatase activity in differentiating cultures of primary osteoblasts. These findings
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suggest that signaling pathways activated by LPAi promote gene expression associated with 
osteogenesis. Indeed, Gennero and coworkers demonstrated that bone marrow stromal cells 
from LPA f 1' mice showed decreased alkaline phosphatase, collagen and osteocalcin expression, 
but no reduction in mineralization (Gennero et al. 2011). Further investigation is required to 
elucidate LPA-induced changes in gene expression in osteoblasts. Microarray and real-time RT- 
PCR analyses would permit the study of gene expression patterns associated with LPA- 
enhanced osteogenesis.
In summary, we have established that functional LPA receptors are present in cells of the 
osteoblast lineage. These receptors induce elevation of [Ca ]j, evoke morphological changes, 
and promote differentiation and mineralization through pathways involving G; and Rho- 
associated protein kinase. In vivo, LPA may regulate the function of osteoblasts and other cell 
types during remodeling and regeneration. LPA may also be of significance in cancer cell
metastasis and metabolic bone diseases.
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